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Abstract 
 
Background: Various studies have demonstrated an association between exposure 
to pesticides and adverse respiratory health outcomes including non-specific 
respiratory symptoms, rhinitis and asthma. Few studies have investigated the 
relationship between pesticide metabolites and asthma outcomes and only a limited 
number have explored mechanisms for allergic and non-allergic airway inflammation 
in individuals exposed to pesticides. A previous sub-study of this group reported an 
association between allergic airway inflammation as determined by fractional exhaled 
nitric oxide (FeNO) and low levels of whole blood cholinesterase among women farm 
workers. The main objective of this study was to investigate the relationship between 
exposure to different pesticides (ascertained through pesticide metabolites 
concentrations in urine) and asthma phenotypes (based on respiratory symptoms, 
cytokine patterns and exhaled nitric oxide profiles) among rural women in the 
Western Cape Province. 
 
Methods: A cross-sectional study was conducted among rural women working and 
living on the farms (farm dwellers, n=121) and those residing in the neighbouring 
towns (town dwellers, n=90). Pesticide exposure was assessed based on urinary 
metabolite concentrations of organophosphate (OP) and pyrethroid (PYR) residues. 
Health outcome assessment was ascertained through modified European 
Community Respiratory Health Survey questionnaire, FeNO concentrations, serum 
cytokine (Th2 and non-Th2 markers) concentrations, and immunological markers for 
atopy (Phadiatop) and specific IgE to house dust mite, storage mite and spider mite. 
  
Results: The median age of the study participants was 37 years (interquartile range: 
28 - 45 years). The urinary concentration (median and interquartile range) of 
pesticide residue metabolites for OP (sum of the 6 dialkyl phosphate metabolites) = 
134 (42-229) µg/g of creatinine; 3,5,6-trichloropyridinol (TCPY) = 5 (3-10) µg/g of 
creatinine; and for PYR (sum of the 5 PYR metabolites) = 6 (3-10) µg/g of creatinine. 
The prevalence of current asthma (asthma attack in the last 12 months or currently 
taking asthma medication) was 6%; doctor diagnosed asthma was 11%; and adult-
onset asthma (history of doctor-diagnosed asthma and first asthma attack at age 16 
years or older) was 9%. The proportion of subjects with FeNO above 50 ppb was 7% 
and between 25-50 ppb was 11%. The proportion of Th2 cytokines (IL-4, IL-5 and IL-
13) detected ranged from 18% to 40% while non-Th2 cytokines (IL-6, IL-8, IL-10, IL-
17 and interferon-γ) ranged from 35% to 71%. IL-8 was the most commonly detected 
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(71%) cytokine while IL-5 was the least detected (18%). Most OP metabolites were 
positively associated with FeNO levels above 50ppb. Both Th2 and non-Th2 
cytokines were positively associated with either OP or PYR metabolites. Non-Th2 
cytokines showed stronger associations with OP metabolites, the strongest 
association between diethyl dithiophosphate (DEDTP) and interferon-γ: prevalence 
odds ratio (95% confidence interval) = 25 (8-78). 
 
Conclusion: OP and PYR urinary metabolite levels in rural women in the Western 
Cape are higher than in the general population. This study provides evidence 
suggesting that both OP and PYR pesticides are associated with asthma, which may 
be due to Th2 and non-Th2 mechanisms, the latter pathway demonstrating 
consistently stronger relationships.  
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1. INTRODUCTION 
 
1.1. BACKGROUD 
 
Pesticides are substances used extensively worldwide to kill or control certain forms 
of unwanted animal or plant life. Pesticides are widely used in agriculture and in 
several other settings including households, schools, leisure areas and also in the 
transportation facilities such as aeroplanes and boats [1,2].  Since pesticides are 
extensively used in the agricultural sector and a significant number of economically 
active South African population is employed in this sector, pesticides pose a 
significant public health problem. 
 
1.2. REVIEW OF THE LITERATURE 
 
Despite their useful effects, pesticides have been associated with various health 
effects including adverse respiratory health outcomes such as asthma, rhinitis and 
non-specific respiratory symptoms.  
 
In summary, the following specific pesticides have been associated with various 
adverse respiratory health outcomes including asthma: organophosphate (OP) 
insecticides: diazinon, parathion, coumaphos, phorate, malathion, chlorpyrifos, 
terbufos, dichlorvos and fonofos; carbamate insecticide, carbaryl; organochlorine 
insecticides: chlordane, heptachlor, lindane and DDT 
(dichlorodiphenyltrichloroethane); pyrethroid (PYR) insecticide, permethrin; 
herbicides: 2,4,5-TP (2,4,5-trichlorophenoxypropionic acid), paraquat, diquat, EPTC 
(ethyl dipropylthiocarbamate), 2,4-D (2,4-dichlorophenoxyacetic acid), glyphosate, 
atrazine, chlorimuro -ethyl, imazethapyr, metolachlor, metribuzin, pendimethalin, 
petroleum oil, alachlor and trifluralin; fungicides: captan, metalaxyl and benomyl; and 
fumigants: ethylene dibromide and 80/20 mix [3–10].  
 
A few other studies have demonstrated an association between different adverse 
respiratory health outcomes and the exposure to broad groups of pesticides but the 
specific pesticides were not identified [11–15].  
 
Exposure assessment for pesticides – biomonitoring approaches 
 
Acetylcholinesterase measurements in blood have been used to estimate exposure 
to organophosphate and carbamate insecticides. Several pesticide metabolites have 
also been used to estimate exposure to pesticides, mostly measured in the urine 
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samples. The most commonly measured metabolites for estimating exposure to 
organophosphates are the six dialkyl phosphate (DAP) metabolites [dimethyl 
phosphate (DMP), diethyl phosphate (DEP), dimethyl thiophosphate (DMTP), 
dimethyl dithiophosphate (DMDTP), diethyl thiophosphate (DETP) and diethyl 
dithiophosphate (DEDTP)] [16]. These DAP metabolites are non-specific, meaning 
they reflect exposure to organophosphates but they do not identify a specific 
organophosphate. 3,5,6- trichloropyridinol (TCPY) is a specific metabolite for 
estimating exposure to a commonly used organophosphate, chlorpyrifos. TCPY is 
the most common specific organophosphate metabolite measured [17]. Other less 
commonly measured specific organophosphate metabolites include α and β isomers 
of malathion monocarboxylic acid and malathion dicarboxylic acid for malathion and 
2-isopropyl- 4-methyl-6-hydroxypyrimidine (IMPY) for diazinon [17,18]. 4-nitrophenol 
has been used for estimating exposure to methyl and ethyl parathion but it is also a 
metabolite of EPN (O-ethyl O-(4-nitrophenyl) P-phenylphosphonothioate) and other 
non-organophosphate chemicals [17]. 
 
A metabolite of carbaryl, 1-naphthol has been measured to estimate exposure to this 
commonly used carbamate [17]. For pyrethroid insecticides, 3- phenoxybenzoic acid 
(3PBA) is a non-specific metabolite, common to about 20 synthetic pyrethroids. 
There are other more specific metabolites of pyrethroids that have been measured, 
including 4-fluoro-3-phenoxybenzoic acid (4F3PBA), a metabolite of cyfluthrin; cis-
2,2-dibromovinyl-2,2-dimethylcyclopropane-1-carboxylic acid (DBCA), a metabolite of 
deltamethrin; and cis- and trans-isomers of 2,2-dichlorovinyl-2,2- 
dimethylcyclopropane-1-carboxylic acid (cis- and trans-DCCA) which are metabolites 
of permethrin, cypermethrin and cyfluthrin [17]. 
 
Pathophysiological mechanisms 
 
a) Cytokine pathways in asthma 
 
Over the past few years, allergic airway inflammation that occurs in asthmatic 
individuals has been classified as being either eosinophilic or non-eosinophilic. It is 
widely accepted that eosinophilic airway inflammation is driven by the Th2 response 
[19], particularly so in mild and moderate asthma. However, the inflammatory 
response seen in severe asthma is complex as the Th1 response is also involved 
[19,20]. Th2 response produces several cytokines including IL-3, IL-4, IL-5, IL-9, IL-
10, IL-13 and IL-33 [19,20]; however, the major Th2 cytokines are IL-4, IL-5 and IL-
13. The cytokine IL-4 is thought to be very crucial during early stages of the allergic 
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response (primary sensitisation) since it enhances the differentiation and stimulation 
of Th2 cells and production of IgE from the B cells. The cytokine IL-13 is considered 
to play a major role during secondary allergen exposure as it promotes mucus 
secretion, smooth muscle contraction and airway hyperresponsiveness. Like most 
other Th2 cytokines, IL-5 promotes eosinophil recruitment, differentiation and 
activation [19]. 
 
b) Pesticides and asthma 
 
Many pesticides are irritants and can induce or aggravate pre-existing asthma 
through their interaction with functional irritant receptors in the airways thereby 
inducing neurogenic inflammation [21]. On the other hand, if  corrosive, pesticides 
can also cause direct damage to the airways [21].  
 
Mechanisms by which pesticides act as irritants is explained in detail in a recently 
published review article [21]. In summary, pesticides like other irritants can activate 
transient receptor potential (TRP) receptors located in the neuronal cells (sensory C-
fibers) and other cells including respiratory epithelia and inflammatory cells leading to 
the release of inflammatory neuropeptides thereby triggering neurogenic 
inflammation [21]. An airway neurogenic inflammation is characterized by 
bronchoconstriction, increased mucus secretion and oedema, which are typical 
features of asthma [21]. Nonspecific bronchial hyper-responsiveness and 
consequently asthma symptom  will manifest if this airway inflammation is sustained 
over time [21]. 
 
It has been proposed that organophosphate and carbamate insecticides induce 
asthma through inhibition of acetylcholinesterase [12]. However, chlorpyrifos (an 
organophosphate) has been found to cause airway hyperreactivity in guinea pigs 
through inhibition of the parasympathetic prejunctional muscarinic M2 receptor 
function at doses below those known to cause acetylcholinesterase inhibition [22]. 
Inhibition of M2 receptor function can also cause increased mucus secretion [21]. In 
another animal study, parathion and diazinon (organophosphates) also caused 
airway hyperreactivity through M2 receptor dysfunction without acetylcholinesterase 
inhibition [23]. The exact mechanism through which organophosphates decrease M2 
receptor function in the airway nerves is unknown. A recent study suggested that the 
organophosphate inhibition of M2 receptor function is neither through direct 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
16 
 
pharmacologic antagonism nor through down regulation of M2 receptor expression 
[24]. 
 
Some pesticides can modulate inflammatory response to common allergens, such as  
for instance carbaryl has been found to enhance allergic responses to house dust 
mites in an animal study [25]. Some pesticides may modulate macrophage function. 
In animal studies, oral administration of malathion resulted in an increased 
macrophage function in mice, which was postulated to be due to the release of 
inflammatory mediators (arachidonic acid metabolites and tumour necrosis factor) 
from mast cells [26]. Interestingly, some pesticides may modulate allergic potential of 
other pesticides [27]. The allergic  potential of phenoxyacetic acid herbicide 2,4-D-
butyl and a fungicide, eugenol were increased in mice exposed to parathion and 
methoxychlor [27]. Eugenol and 2,4-D-butyl are known to be contact allergens. 
These mice were found to have increased surface antigen expression of T cells and 
higher numbers of Th1 cytokines (interferon-γ and tumour necrosis factor-α) and 
interleukin (IL)-17 [27]. 
 
Individuals sensitized to common allergens may be more susceptible to the effects of 
pesticides. This has also been shown in animal studies, in which guinea pigs 
sensitized to ovalbumin demonstrated a decreased threshold to parathion-induced 
airway hyperreactivity [28]. Moreover, parathion effects on vagally induced 
bronchoconstriction were exacerbated in these sensitized guinea pigs [28]. 
Interestingly, sensitization also changed the mechanism of parathion-induced 
hyperreactivity from IL-5 independent to IL-5 dependent [28]. 
 
Some pesticides such as a carbamate, carbaryl; a fungicide, zineb; and the three 
herbicides: simazine, alachlor and nitrofen are endocrine disrupters [29]. Endocrine 
disrupters (EDs) are chemicals that not only interfere with the balance of endocrine 
system but also influence immune system [29]. Some evidence exists from animal 
data that demonstrate how EDs can enhance the allergic response. Laboratory 
studies have demonstrated that some EDs such as nonylphenol and octylphenol can 
enhance T helper cells 2 (Th2) development and thereby shifting T helper cells 1 
(Th1) / Th2 balance towards that favouring the Th2 pathway. Th2 response produces 
Th2 cytokines such as IL-4, 5 and 13, consequently leading to increased production 
of immunoglobulin E (IgE) [29].  
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1.3. JUSTIFICATION 
 
This current analysis will be conducted on data previously collected for a study 
investigating the health effects of pesticides among rural women in the Western 
Cape province in South Africa. In this previous sub-study [30] investigating the 
effects of pesticides on asthma, women with having FeNO levels greater than 50 ppb 
had an almost 5 fold increased odds (OR = 4.80; 95% CI: 0.80 - 28.00) of 
cholinesterase (ChE) levels below the laboratory reference standard (6021 IU, Roche 
Diagnostics®) when compared to women with ChE levels above this reference value. 
This finding suggested a probable association between exposure to ChE depressing 
pesticides (organophosphate and carbamate insecticides) and allergic asthma.   
 
In the previous analysis [30] there was however a lack of association between 
various asthma outcomes and sensitisation to allergens such as house dust mites, 
spider mites and storage mites encountered on farms known to cause asthma. It was 
postulated that a possible reason for this was that pesticides to which these women 
were exposed to may be more important respiratory sensitizers causing allergic 
airway inflammation than these indoor and outdoor mites. It is anticipated that this 
current analysis of studying cytokine patterns would shed more light on the 
pathophysiological mechanisms through which these pesticides may be causing 
asthma in this group. 
 
Furthermore, in the previous analysis [30], bio-monitoring was limited to only whole 
blood ChE measurements due to limited resources available in analysing the 
collected urine samples for the presence of pesticide metabolites. However, in the 
current analysis, bio monitoring data was available for several pesticide metabolites 
for characterising the exposure to specific organophosphate and pyrethroid 
pesticides. These included 3,5,6- trichloropyridinol (TCPY) for chlorpyrifos, 4-fluoro-
3-phenoxybenzoic acid (4F3PBA) for cyfluthrin and cis-2,2-dibromovinyl-2,2-
dimethylcyclopropane-1-carboxylic acid (DBCA) for deltamethrin pesticides. 
 
1.4. RESEARCH QUESTIONS 
 
1.4.1. Is pesticide exposure based on objective markers (pesticide metabolites) 
associated with respiratory symptoms and asthma among women farm 
workers in the Western Cape Province of South Africa? 
1.4.2. What cytokine pathways are present in those with respiratory symptoms and 
asthma? 
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1.5. HYPOTHESIS 
 
1.5.1. Pesticide exposure is associated with respiratory symptoms and asthma 
among these women.  
1.5.2. An allergic response involving a Th2 cytokine response is the probable 
mechanism underlying the airway inflammation suggested by elevated FeNO.   
 
1.6. AIM 
 
To determine the association between pesticides metabolites and respiratory health 
outcomes among women farm workers in the Western Cape 
 
1.7. OBJECTIVES 
 
i) To determine the urinary concentration of organophosphate and 
pyrethroid metabolites as markers of short-term pesticide exposure.  
ii) To determine serum concentration of Th1 and Th2 cytokines. 
iii) To investigate the relationship between exposure to different pesticides 
(ascertained through pesticide metabolites concentrations in urine) and 
asthma phenotypes (based on respiratory symptoms, cytokine patterns 
and exhaled nitric oxide profiles), controlling for known confounders.  
 
2. METHODOLOGY 
 
2.1. Study design 
 
This study involves the analysis of a subset of data that was collected in 2009.The 
main study was an analytical cross-sectional study of 211 women from farms and 
towns neighbouring the farms in the Boland region of the Western Cape province of 
South Africa. The main aim of the larger study was to investigate the respiratory, 
neurologic and reproductive health effects associated with pesticide exposure.  
 
2.2. Population and sampling 
 
2.2.1. Study population 
 
The study population included women from the farms and towns neighbouring these 
farms in the Boland region of the Western Cape province of South Africa. There were 
5 areas where the study participants were recruited from: Worcester, Paarl, 
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Stellenbosch, Ceres and Grabouw. The crops grown on the farms were mainly 
common fruits such as grapes, apples, pears, prunes, berries, lemons and oranges. 
 
2.2.2. Sampling strategy 
 
The recruitment of study participants was accomplished by the non-governmental 
organisation, Women on farms (WFP). The research team planned to recruit 100 
women from farms affiliated to WFP and 100 women not living on farms but from the 
neighbouring towns in each study area. The targeted sample was 40 women (20 
each from farms and towns) from each of the 5 study areas. Due to time constraints 
and logistical difficulties, the sample was selected by using a non-random sampling 
method. Farm workers and residents were selected from the 5-10 most accessible 
farms in each area and town residents from the most accessible houses in each 
area. One adult female participant per household was selected. WFP recruited a total 
of 211 women into the study including 113 women currently living on a farm and 98 in 
towns. Eight women lived in the town but worked in the farm, these were included in 
the farm worker group. There were a total of 97 farm workers (89 women living in 
farms and 8 not living in farms). There were 24 women residing but not working on 
farms. The farm workers and residents (n=121) are referred to as “Farm dwellers”. 
There were 90 women who neither lived nor worked on a farm and they are referred 
to as “Town dwellers. 
 
2.2.3. Sample size calculations 
 
Using results from a recently published study [31], the calculated sample size using a 
two sample comparison of proportions (exposed/control ratio = 1, power = 90%, 
confidence level = 95%) to detect a 2.25 fold increase in asthma prevalence (20% to 
45%) is 160 participants. 
 
2.3. Study instruments 
 
2.3.1. Questionnaire 
 
Trained interviewers administered questionnaires (Appendix A1 and A2) to 
participants in their language of choice. Briefly, the questionnaire had sections on 
socio-demographic factors, residential history, household pesticide exposure, 
environmental pesticide exposure, job history, lifestyle factors and respiratory health. 
The respiratory health section was a modified version of the European Community 
Respiratory Health Survey questionnaire [32]. The other sections of the questionnaire 
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were based on the previous surveys conducted in South Africa [3,33].The 
questionnaires were translated into Afrikaans and Xhosa and thereafter back 
translated to ensure accuracy of the translation. 
 
2.3.2. Pesticide metabolite determination 
 
Spot urinary samples (50 ml) were collected in plastic containers topped with a 
plastic cap and kept on dry ice in the field and during transport and then stored at -20 
degrees Celsius before being sent to the laboratory for analysis.  The urine samples 
were couriered to National Institute for Occupational Health (NIOH) laboratory in 
Johannesburg which has already set up methods for measuring the 
organophosphate pesticide metabolites, dialkyl phosphates, the chlorpyrifos 
metabolite, 3,5,6-trichloropyridinol (TCPY) and the pyrethroid metabolites. 
 
An insecticide screen that employs a high performance liquid 
chromatography/tandem mass spectrometry-based method and quantification using 
the isotope dilution (ID) calibration [34] was used to screen urine for 
organophosphate and pyrethroid insecticides.  Briefly, using ID calibration, the 
samples were enriched with isotopically labelled analogues prior to preparation.  
Chemically the isotope analogue behaves identically to the native analyte, but can be 
discriminated with a mass filter [35].  This allows complete recovery correction for 
each sample and improves the sensitivity, accuracy, and selectivity of the analysis.  
After addition of the labelled standard to urine samples, glucuronide or sulfate-bound 
urinary metabolites were liberated by enzyme hydrolysis and the analytes were 
isolated using solid phase extraction.  The extractants were concentrated to dryness 
and reconstituted in solvent for analysis by ID-high performance liquid 
chromatography-atmospheric chemical ionization-tandem mass spectrometric 
(MS/MS).  Five pyrethroid metabolites [3- phenoxybenzoic acid (3PBA); 4-fluoro-3-
phenoxybenzoic acid (4F3PBA); cis-2,2-dibromovinyl-2,2-dimethylcyclopropane-1-
carboxylic acid (DBCA) and cis- and trans-isomers of 2,2-dichlorovinyl-2,2- 
dimethylcyclopropane-1-carboxylic acid (cis- and trans-DCCA)]   and seven 
organophosphate metabolites [TCPY and the six dialkyl phosphate (DAP) 
metabolites [dimethyl phosphate (DMP), diethyl phosphate (DEP), dimethyl 
thiophosphate (DMTP), dimethyl dithiophosphate (DMDTP), diethyl thiophosphate 
(DETP) and diethyl dithiophosphate (DEDTP)]] were screened.  Results were 
adjusted for concentration by creatinine.  The limit of detection (LOD) for all analytes 
was determined.    
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2.3.3. Serum cytokines determination 
 
All blood samples were collected during the afternoon and early evening to 
accommodate those who were working during the day. A blood sample (9 ml) was 
drawn from each participant using a Becton Dickinson Vacutainer SST tube (with gel 
medium and clot activator) by the qualified nurse. The blood was allowed to clot for 
1-2 hours at room temperature (20-24 degrees Celsius) and then centrifuged at 
1350g for 10 minutes at room temperature. The serum was then transferred to 
another tube and stored at -20 degrees Celsius in a field freezer. The stored serum 
sample was transported on dry ice to the School of Public Health and Family 
Medicine, University of Cape Town where it was stored at -80 degrees Celsius until 
assayed for further measurement. The samples were couriered to the NIOH 
Immunology laboratory for testing. Some part of the serum was used for other 
immunology tests in the original study (sensitisation to house dust mite, storage mite 
and spider mite). The remaining amount of serum was used for cytokine analysis. 
The BDTM CBA Human Inflammation kit was used to quantitatively measure non-
allergic inflammatory interleukin (IL-8, IL-6, IL-10, IL-17, interferon gamma) protein 
levels in each serum sample.  Six bead populations with distinct fluorescence 
intensities coated with the specific interleukins were multiplexed and resolved in the 
red channel of the flow cytometer (BD FacsArrayTM) (Becton Dickson, Oxford, UK).  
The inflammatory interleukins associated with allergy (IL-4, IL-5, IL-13) were 
measured using the BDTM CBA Human Soluble Protein Flex Set assay according to 
the manufacturer’s instructions. The assay allow for multiplexed analysis of multiple 
proteins from a single sample.  The concentrations were determined using the 
(FacsArrayTM) (Becton Dickson, Oxford, UK). 
 
2.3.4. Fractional exhaled nitric oxide (FeNO) determination 
 
Fractional exhaled nitric oxide measurement is a recognised non-invasive method for 
the assessment of allergic airway inflammation [36,37]. Under the guidance of an 
experienced nurse, FeNO levels were determined from single-breath exhalations 
(Appendix B and C). The technique involved inspiration of nitric oxide (NO)-free air 
via a mouthpiece to total lung capacity, followed immediately by full exhalation at an 
even rate through the mouthpiece into the apparatus. A hand-held portable nitric 
oxide sampling device (NIOX MINO® Airway Inflammation Monitor (NIOX MINO); 
Aerocrine AB, Solna, Sweden) was used. Three technically adequate measurements 
were performed in line with the current American Thoracic Society /European 
Respiratory Society recommendations [38]. The FeNO test was done after hours 
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during the working week. Special instructions were provided to workers to ensure 
that tested individuals do not smoke tobacco, eat or drink (at least 1 hour before) 
prior to the test. The participants’ height and weight were measured and this 
information was used to calculate BMI. Ambient NO and temperature were also 
recorded. 
 
2.4. List and definition of variables 
 
2.4.1. Exposure variables 
 
The exposure variables of interest will be: 
(a) Organophosphate metabolite concentrations in urine: 
(i) TCPY 
(ii) Six DAP metabolites (DMP, DEP, DMTP, DMDTP, DETP a d DEDTP) 
(b) Pyrethroid metabolites (3PBA; 4F3PBA; DBCA and cis-DCCA and trans-DCCA] 
They are all continuous variables but they may be categorised if necessary. 
  
2.4.2. Outcome variables 
 
The following outcome variables will be used for this analysis: 
(a) Doctor-diagnosed asthma 
(b) FeNO levels: 
Two binary variables 
                   - Probable allergic asthma: FeNO > 50ppb  
- Possible allergic asthma: FeNO 25-50ppb  
(c) Current asthma: Yes to at least one of the following 2 questions: “Have you had 
an attack of asthma in the last 12 months?” or “Are you currently taking 
any medicines including inhalers, aerosols or tablets for asthma?”  
(d) Adult-onset asthma: doctor-diagnosed asthma and having had the first asthma 
attack at the age of 16 years or later 
(e) Cytokines levels (binary variable categorised as detected vs. non-detected)  
Type 1 (non-allergic) and Type 2 (allergic) pattern of elevated cytokines 
  
2.4.3. Covariates 
 
Potential confounders that will be considered include current smoking (binary 
variable), atopy (binary variable based on Phadiatop test), years of schooling 
(continuous variable), born on a farm (binary variable), age (continuous variable), 
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BMI (a continuous variable), employment (binary variable) and household income 
(continuous variable). 
 
2.5. Pilot study 
 
All study tools were piloted prior to the main study. The fieldwork for the main study 
was conducted during the period 24 October - 3 December 2009. 
 
2.6. Data management and analysis plan 
 
The database with data input from the questionnaires will be analysed using Stata 
statistical package version 12 [39]. Exploratory data analysis will be carried out to 
highlight general features of the data including running descriptive checks to 
determine the number of observations, the type of variables, presence of outliers, the 
nature of data cleaning required and the extent of missing data as well as the 
distributions of the key variables. Descriptive statistics will be calculated to 
summarize the data. Bivariate analyses will be conducted to assess the nature of the 
associations between exposures, outcomes and covariates. Multivariate regression 
analysis will be applied to examine the association between the dependent and 
independent variables. Confounding by covariates will be considered in the 
formulation of the models. 
 
3. ETHICS AND COMMUNICATION 
 
The main study was approved by the University of Cape Town’s Human Research 
Ethics Committee (Reference 393/2009) (Appendix D and E). The study was 
conducted in accordance with the Declaration of Helsinki [40].     
 
3.1. Autonomy 
 
Women were approached to participate in the study on voluntary basis. A written 
informed consent (Appendix F1 and F2) was obtained from all study participants 
before participation. Confidentiality of participants’ information has been preserved, 
only the research team have access to the data. The study participants have been 
assigned unique numbers and only group results will be disseminated.  
 
3.2. Benefit 
 
The study participants were informed of their study findings and those with abnormal 
results were referred to their medical practitioners. The study findings will provide 
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more information about the levels of pesticide exposure in these women and their 
relationship with various respiratory health outcomes including asthma. This 
information can be used by different stakeholders in the effort to improve health of 
women on the farms.  
 
3.3. Non-maleficence 
 
There was no harm to the study participants except for the minor discomfort of the 
needle prick during blood sample collection. There will be no additional risks to the 
study participants because this current analysis does not require their participation. 
 
3.4. Justice 
 
The reports of respiratory and other health problems among the women in the study 
site justified the study to be conducted at that particular area. 
 
3.5. Dissemination of research results: 
 
This study is conducted for the partial fulfilment of Master of Medicine (MMED) 
degree. The final report will be submitted to the University of Cape Town for marking. 
The study findings will be published in a suitable academic peer-reviewed journal and 
presented at local and international conferences. A report will be submitted to the 
stakeholders including the Non-Governmental Organization, Women on Farms 
Project (WFP). 
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THE RELATIONSHIP BETWEEN PESTICIDE RESIDUES AND 
ASTHMA OUTCOMES AMONG WOMEN FARM WORKERS 
 
1. INTRODUCTION 
 
1.1. BACKGROUD 
 
Pesticides are substances used extensively worldwide to kill or control certain forms 
of unwanted animal or plant life. Pesticides are widely used in agriculture and in 
several other settings including households, schools, leisure areas and also in the 
transportation facilities such as aeroplanes and boats [1,2].  Despite their useful 
effects, pesticides have been associated with various health effects including 
respiratory health outcomes such as asthma, rhinitis and non-specific respiratory 
symptoms. Since pesticides are extensively used in the agricultural sector and a 
significant number of economically active South African population is employed in 
this sector, pesticides pose a significant public health problem. 
 
1.2. OBJECTIVES OF THE LITERATURE REVIEW 
 
The focus of this literature review was to obtain information on exposure 
characterisation of pesticides (biomonitoring data), specific pesticides associated 
with various respiratory health outcomes with a specific focus on asthma, exposure-
response relationships, and the pathophysiological mechanisms involved with a 
particular focus on cytokine pathways.  
 
1.3. SEARCH STRATEGY 
 
Several electronic sources of information were searched for relevant articles 
including PubMed, Embase and Google Scholar using various key words: allergy, 
asthma, rhinitis, pesticides, organophosphates, pyrethroids, biological monitoring, 
dialkyl phosphate, trichloropyridinol, acetylcholinestrase, T helper cells, cytokines, 
interleukins, farm workers and farmers. Reference lists from the articles obtained 
were also screened for relevant publications. Information was also sought from non-
electronic sources such as dissertations and text books.  
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2. SPECIFIC PESTICIDES ASSOCIATED WITH ASTHMA 
 
Several epidemiological studies have reported an association between exposure to 
pesticides and respiratory health effects such as asthma and rhinitis. Exposures to 
pesticides in these studies have ranged from acute high pesticide exposure events to 
chronic exposures. Information on the specific pesticides that have been associated 
with different respiratory health outcomes is summarised in Table 1. 
  
2.1. Insecticides 
 
2.1.1. Organophosphate and carbamate insecticides 
 
Organophosphate and carbamate insecticides inhibit acetylcholinestrase activity. 
However, while organophosphates irreversibly inhibit acetylcholinesterase, inhibition 
by carbamates is reversible [3,4]. Organophosphates and carbamates pesticides 
have shown stronger associations with adverse respiratory health outcomes than 
other pesticides. In the Agricultural Health Study (AHS) [5], allergic asthma was 
significantly associated with three organophosphate insecticides: diazinon (odds ratio 
(OR) = 1.57; 95% confidence interval (CI): 1.05 – 2.35), parathion (OR = 2.05; 95% 
CI: 1.21 – 3.46) and coumaphos (OR = 2.34; 95% CI: 1.49 – 3.70). On the other 
hand, phorate (OR = 1.29; 95% CI: 1.01 – 1.65) and malathion (OR = 1.35; 95% CI: 
1.04 – 1.75) showed significant association with nonallergic asthma [5]. Another 
study reported by the AHS demonstrated a significant association between adult 
onset doctor diagnosed asthma and use of 4 organophosphates; coumaphos (OR = 
2.19; 95% CI: 1.02 - 4.69), malathion (OR = 1.60; 95% CI: 1.22 – 2.10), parathion 
(OR = 2.88; 95% CI: 1.34 – 6.20) and phorate (OR = 2.04; 95% CI: 1.07 – 3.88) [6]. 
The decrease in plasma cholinesterase of more than 25% was significantly 
associated (p= 0.018) with a decrease in forced expiratory volume in one second 
(FEV1) among Spanish agricultural workers, suggesting an association between 
short-term exposure to acetylcholinesterase inhibiting pesticides and lung 
dysfunction [7]. Kenyan farm workers with more than 30% inhibition in 
acetylcholinesterase activity also reported higher rates of respiratory symptoms 
(prevalence ratio 2.92; 95% CI: 1.12 - 7.61) compared to those without inhibition [8].  
 
Wheeze was strongly associated with reported exposures to two organophosphates; 
chlorpyrifos (OR = 6.7; 95% CI: 1.6 – 28.0) and terbufos (OR = 5.9; 95% CI: 1.4 – 
25.6) among non-smoking farm women in Costa Rica [9]. In the AHS [10], wheeze 
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was significantly associated with five organophosphates; chlorpyrifos (OR = 1.47; 
95% CI: 1.09 - 1.99), dichlorvos (OR = 2.48; 95% CI: 1.09 - 5.64), fonofos (OR = 
1.78; 95% CI: 1.07 - 2.98), phorate (OR = 2.87; 95% CI: 1.70 - 4.84), terbufos (OR = 
1.66; 95% CI: 1.09 - 2.53). Three organophosphates chlorpyrifos (OR = 1.12; 95% 
CI: 1.01 - 1.25), malathion (OR = 1.14; 95% CI: 1.02 - 1.28), parathion (OR = 1.50; 
95% CI: 1.04 – 2.16), were associated with wheeze in another sub-study of the AHS 
[11].  
 
Local case reports of two farm workers engaged in pesticides spraying in a large fruit 
farm in the Western Cape, South Africa who complained of respiratory symptoms 
had markedly decreased levels of plasma cholinesterase[12]. While one complained 
of ‘asthma’, the other one complained of ‘chronic bronchitis’ [12]. Several chemicals 
were used in this farm including two organophosphates, chlorpyrifos and azinphos-
methyl [12]. A nursery worker from the same farm, also exposed to insecticides 
suffered from ‘asthma’ [12]. 
 
Organophosphates have also been associated with other respiratory symptoms such 
as rhinitis. Diazinon was found to be significantly associated (OR = 1.84; 95% CI: 
1.23 – 2.75) with current rhinitis in the AHS [13]. Four organophosphate insecticides; 
dichlorvos (OR = 1.15; 95% CI: 1.03 - 1.28), chlorpyrifos (OR = 1.06; 95% CI: 1.01 - 
1.11), diazinon (OR = 1.12; 95% CI: 1.03 - 1.21) and malathion (OR = 1.06; 95% CI: 
1.01 - 1.11) were significantly associated with current rhinitis among AHS private 
pesticide applicators [14].   
 
Use of carbamate insecticides was significantly associated (prevalence odds ratio, 
POR = 1.9; 95% CI: 1.2 - 3.0) with reported asthma among male farmers in 
Saskatchewan, Canada [3]. Carbamates used by these farmers include carbofuran, 
methomyl, and carbaryl [3]. Atopic asthma was significantly associated (OR = 1.41; 
95% CI: 1.10 – 1.80) with the use of carbaryl in the AHS [6]. However, there was no 
significant association between nonatopic asthma and use of the two carbamate 
insecticides (carbaryl and carbofuran) analysed in this study [6]. Carbamate use was 
also strongly associated (OR = 2.4; 95% CI: 1.0 – 6.0) with allergic rhinitis among 
grape farmers in Greece [15].  
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2.1.2. Organochlorine insecticides 
 
Three organochlorines; chlordane (OR = 1.77; 95% CI: 1.19 – 2.63), heptachlor (OR 
= 2.01; 95% CI: 1.30 – 3.11) and lindane (OR = 1.57; 95% CI: 1.01 – 2.41) were 
modestly associated with allergic asthma in the AHS [5]. However in this study [5], 
nonallergic asthma was statistically significantly associated with only one 
organochlorine, dichlorodiphenyltrichloroethane (DDT). Not only is DDT use 
associated with nonallergic asthma, in another sub-study of the AHS [6], DDT use 
was also associated (OR = 1.79; 95% CI: 1.06 – 3.03) with allergic asthma.  
 
2.1.3. Pyrethroids 
 
Permethrin application on animals has also been associated (OR = 1.71; 95% CI: 
1.01 – 2.91) with atopic asthma in the AHS [6]. On the other hand, permethrin use on 
crops is associated (OR = 2.19; 95% CI: 1.33 – 3.61) with nonatopic asthma 
[6].Wheeze in the past year is also associated with permethrin use in animals (OR = 
1.28; 95% CI: 1.06 – 1.55) [16] and permethrin use in poultry (OR = 1.26; 95% CI: 
1.06 – 1.51) [11] in the AHS. Use of permethrin on animals has also been mildly 
associated (OR = 1.13; 95% CI: 1.03 – 1.23) with current rhinitis in the AHS [14]. 
 
2.2. Herbicides 
 
Three herbicides; (RS)-2-(2,4,5-trichlorophenoxy)propionic acid (2,4,5-TP) (OR = 
1.91; 95% CI: 1.06 – 3.44) , S-ethyl dipropyl(thiocarbamate) (EPTC) (OR = 1.61; 
95% CI: 1.06 – 2.43) and paraquat (OR = 1.67; 95% CI: 1.05 – 2.65) were 
moderately associated with allergic asthma in the AHS [5]. Allergic asthma has also 
been associated with two herbicides; 2,4-dichlorophenoxyacetic acid (2,4-D) (OR = 
1.53; 95% CI: 1.12 – 2.10) and glyphosate (OR = 1.31; 95% CI: 1.02 – 1.67) [6].  
 
Several herbicides have also been associated with wheeze. Wheeze in the past year 
was associated with the use of 6 herbicides; alachlor (OR = 1.23; 95% CI: 1.06 – 
1.41), atrazine (OR = 1.18; 95% CI: 1.05 – 1.32), chlorimuron-ethyl (OR = 1.62; 95% 
CI: 1.25 – 2.10), EPTC , (OR = 1.37; 95% CI: 1.08 – 1.73) petroleum oil (OR = 1.26; 
95% CI: 1.09 – 1.47) and trifluralin (OR = 1.15; 95% CI: 1.02 – 1.30) [16]. In another 
sub-study of the AHS [10], current use of 8 herbicides (atrazine, chlorimuron-ethyl, 
glyphosate, imazethapyr, metolachlor, metribuzin, pendimethalin and petroleum oil) 
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was  associated with current wheeze. Furthermore, alachlor, atrazine, chlorimuron-
ethyl, EPTC, paraquat, petroleum oil and trifluralin have also demonstrated 
associations with current wheeze in an earlier study [11]. In a South African study 
among fruit farm workers [17], long term exposure to paraquat was significantly 
associated with exercise oxygen desaturation. Interestingly no association was found 
with the other respiratory outcomes (respiratory symptoms, spirometry, carbon 
monoxide gas transfer or chest radiography).  
 
Studies of pesticide effects on upper airways have shown that rhinitis was associated 
with the use of glyphosate and petroleum oil among commercial pesticide applicators 
[13] as well as among private pesticide applicators [14] in the AHS. Use of 2,4-D was 
also associated (OR = 1.34; 95% CI: 1.09 – 1.64) with current rhinitis among 
commercial pesticide applicators [13]. Allergic rhinitis demonstrated associations with 
glyphosate (OR = 2.5; 95% CI: 1.0 – 6.5) and bipyridyls which includes paraquat and 
diquat (OR = 4.0; 95% CI: 1.4 - 11.2) [15]. 
 
2.3. Fungicides 
 
Allergic asthma has is associated with fungicides; captan (OR = 1.83; 95% CI: 1.15 – 
2.94) [5], and metalaxyl (OR = 2.61; 95% CI: 1.35 – 5.04) [6]. Metalaxyl has also 
been associated (OR = 1.19; 95% CI: 1.02 – 1.38) with current wheeze [11]. Another 
fungicide, benomyl , demonstrated associations with (OR = 2.35; 95% CI: 1.11 – 
4.98) with current rhinitis [13]. Captan use was more prevalent with increased 
episodes of rhinitis, the strongest association being between 7–12 episodes of rhinitis 
in past year (OR = 1.32; 95% CI: 1.17 – 1.49) [14]. In a study conducted among 
workers in Greece, allergic rhinitis was associated with dithiocarbamates (OR = 3.5; 
95% CI: 1.2 - 10.2), thiophthalimide (OR = 3.3; 95% CI: 1.2 – 8.7) and triazole (OR = 
2.7; 95% CI: 1.0 – 7.0) [15].  
 
2.4. Fumigants 
 
Two fumigants; ethylene dibromide (OR = 2.07; 95% CI: 1.02 – 4.20) and 80/20 mix 
(carbon tetrachloride and carbon disulfide) (OR = 2.15; 95% CI: 1.23 – 3.76) have 
been reported with increased odds of  with allergic asthma in the AHS [5].  
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Table 1: Pesticides associated with various respiratory outcomes 
 
Pesticide Respiratory outcome Reference 
Type 
 
 
Chemical 
Group 
Active ingredients 
Insecticide 
 
 
 
 
Herbicide 
 
Fungicide 
 
Fumigants 
Organophosphate 
 
 
Organochlorine   
 
 
 
Diazinon, parathion, coumaphos 
 
 
Chlordane, heptachlor, lindane 
 
2,4,5-TP, paraquat,  EPTC 
 
Captan  
 
Ethylene dibromide, 80/20 mix 
Adult onset allergic 
asthma (doctor-
diagnosed asthma after 
the age of 19 years with 
history of doctor-
diagnosed eczema or 
hay fever) 
[5] 
Insecticide Organophosphate 
 
Organochlorine 
Phorate, malathion 
 
DDT 
Adult onset non-allergic 
asthma (doctor-
diagnosed asthma after 
the age of 19 years 
without history of doctor-
diagnosed eczema or 
hay fever ) 
[5] 
Insecticide 
 
 
 
 
 
 
Herbicide 
 
Fungicide 
Organophosphate 
 
 
Carbamate 
 
Pyrethroid 
Coumaphos, malathion, parathion, 
phorate 
 
Carbaryl 
 
Permethrin (on animals)  
 
2,4-D, glyphosate 
 
Metalaxyl 
Adult onset allergic 
asthma (doctor-
diagnosed asthma after 
the age of 19 years with 
history of doctor-
diagnosed eczema or 
hay fever) 
[6] 
 Organochlorine 
 
Pyrethroid 
DDT 
 
Permethrin (on crops) 
Adult onset non-allergic 
asthma (doctor-
diagnosed asthma after 
the age of 19 years 
without history of doctor-
diagnosed eczema or 
hay fever ) 
[6] 
Herbicide  Paraquat Exercise oxygen 
desaturation 
[17] 
Insecticide ACHE inhibiting 
pesticides 
Not specified Forced expiratory volume 
in one second (FEV1) 
[7] 
Insecticide ACHE inhibiting 
pesticides 
Not specified Respiratory symptoms 
(chest pain, cough, 
running nose, wheezing, 
difficulties in breathing, 
shortness of breath & 
irritation of the throat). 3 
or more were considered 
positive 
[8]  
Insecticide Organophosphate Chlorpyrifos, terbufos Wheezing or whistling 
sounds in the chest in the 
past 12 months, without 
having a cold or flu 
[9] 
 
 
 
Herbicide 
Organophosphate Chlorpyrifos, terbufos, dichlorvos, 
fonofos, phorate 
 
Atrazine, chlorimuron-ethyl, 
glyphosate, imazethapyr, 
metolachlor, metribuzin, 
pendimethalin,  petroleum oil 
Wheezing or whistling in 
the chest in the past 12 
months 
[10] 
Insecticide 
 
Organophosphate 
 
Chlorpyrifos, malathion, parathion 
 
Wheezing or whistling in 
the chest in the past 12 
[11] 
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Herbicide 
 
 
 
Fungicide 
Pyrethroid Permethrin (on poultry) 
 
Alachlor, atrazine, chlorimuron-
ethyl, EPTC, paraquat, petroleum 
oil, trifluralin 
 
Metalaxyl 
months  
Insecticide 
 
Herbicide 
Pyrethroid Permethrin (on animals) 
 
Alachlor, atrazine, chlorimuron-
ethyl, EPTC, petroleum oil, trifluralin 
Wheezing or whistling in 
the chest in the past 12 
months 
[16] 
Insecticide Organophosphate Not specified Nursing sister diagnosed 
asthma and chronic 
bronchitis 
[12] 
Insecticide Carbamate  Not specified Doctor-diagnosed 
asthma 
[3] 
Insecticide 
 
Herbicide 
 
Fungicide 
Organophosphate Diazinon  
 
Glyphosate, petroleum oil, 2,4-D 
 
Benomyl  
Stuffy, itchy or runny 
nose in the past 12 
months 
[13] 
Insecticide 
 
 
 
 
Herbicide 
 
Fungicide 
Organophosphate 
 
 
Pyrethroid 
 
Dichlorvos, chlorpyrifos, diazinon, 
malathion 
 
Permethrin (on animals) 
 
Glyphosate, petroleum oil 
 
Captan  
Stuffy, itchy or runny 
nose in the past 12 
months 
[14] 
Insecticide 
 
 
 
Herbicide 
 
Fungicide 
Carbamate 
 
 
 
Bipyridyl  
 
Dithiocarbamates, 
thiophthalimides, 
triazoles  
Not specified 
 
Glyphosate, 
 
Paraquat, diquat 
 
Not specified 
Two or more nasal 
symptoms (rhinorrhoea, 
sneezing, nasal 
obstruction and nasal 
itching) during the last 12 
months, apart from a cold 
PLUS positive skin prick 
test (SPT) and/or a 
positive enzyme 
immunoassay test 
[15] 
2,4,5-TP: 2,4,5-trichlorophenoxypropionic acid; EPTC: ethyl dipropylthiocarbamate;  
DDT: dichlorodiphenyltrichloroethane; 2,4-D: 2,4-dichlorophenoxyacetic acid 
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3. DOSE – RESPONSE RELATIONSHIPS 
 
There are few studies that have investigated dose-response relationships between 
pesticide exposure and respiratory health outcomes [5,6,11,13,14,18]. In the recently 
published AHS among male farmers [5], ten of the 12 pesticides associated with 
allergic asthma had demonstrable dose-response relationships. Although a history of 
ever-use of 2,4-D, 2,4,5-T ((2,4,5-trichlorophenoxy)- acetic acid) and permethrin on 
animals was not significantly associated with allergic asthma, these insecticides 
demonstrated significant dose-response trends for allergic asthma [5]. Overall, the 
specific pesticides that showed a significant dose-response relationship with allergic 
asthma in this study included two organophosphates: coumaphos and parathion; 
three organochlorines: chlordane, heptachlor and lindane; one pyrethroid: permethrin 
used on animals; four herbicides: 2,4,5-T, 2,4,5-TP, 2,4-D and EPTC; one fungicide: 
captan and two fumigants: 80/20 mix and ethylene dibromide [5]. On the other hand, 
DDT and malathion demonstrated statistically significant dose-response relationships 
for non-allergic asthma [5]. However, there were no significant dose-response trends 
observed between pesticide exposure variables and asthma among women farmers 
in the AHS [6]. 
 
Studies among South Korean farmers demonstrated significant dose-response 
trends between restrictive ventilatory defects and paraquat exposure variables: 
paraquat application years (p=0.015 for trend) and lifetime paraquat application days 
(p=0.007 for trend) [18]. However, there were no significant dose-response 
relationships for obstructive ventilatory defects [18]. 
 
Pesticide use has also been shown to have significant dose-response relationships 
with wheeze. The odds of wheeze increased with the duration of pesticide for one 
herbicide chlorimuron-ethyl (p= 0.012 for trend), and two organophosphates; 
chlorpyrifos (p= 0.003 for trend) and phorate (p= 0.010 for trend) among commercial 
pesticide applicators in the AHS [10]. In another sub-study of the AHS [16], all these 
three pesticides (chlorimuron-ethyl, chlorpyrifos and phorate) demonstrated  
significant dose-response relationships for wheeze among commercial pesticide 
applicators, while only chlorimuron-ethyl and chlorpyrifos demonstrated significant 
dose-response trends among farmers. Parathion, malathion, chlorpyrifos, 2,4-D, 
atrazine, alachlor, EPTC, paraquat and carbaryl demonstrated significant dose-
response relationships with wheeze [11]. 
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The odds of rhinitis increased significantly with the duration of use of petroleum oil 
and diazinon [13]. Petroleum oil also showed significant dose-response trends with 
rhinitis in another study among private pesticide applicators [14]. In this latter study 
[14], the use of permethrin on animals also demonstrated significant dose-response 
relationships with rhinitis episodes. 
 
4. EXPOSURE ASSESSMENT FOR PESTICIDES – BIOMONITORING 
APPROACHES 
 
Traditionally, acetylcholinesterase measurements in blood have been used as a 
proxy for estimating exposure to organophosphate and carbamate insecticides. With 
increasing laboratory analytical capabilities, several pesticide metabolites, commonly 
measured in the urine samples, have also been used to estimate exposure to 
pesticides. The most commonly measured metabolites for estimating exposure to 
organophosphates are the six dialkyl phosphate (DAP) metabolites [dimethyl 
phosphate (DMP), diethyl phosphate (DEP), dimethyl thiophosphate (DMTP), 
dimethyl dithiophosphate (DMDTP), diethyl thiophosphate (DETP) and diethyl 
dithiophosphate (DEDTP) [19]. These DAP metabolites are non-specific, in that they 
reflect short-term exposure to organophosphates but are not able to identify a 
specific organophosphate. The metabolite 3,5,6- trichloropyridinol (TCPY), on the 
other hand,  is a specific metabolite frequently measured for estimating exposure to a 
commonly used organophosphate, chlorpyrifos [20]. Other less commonly measured 
specific organophosphate metabolites include α and β isomers of malathion 
monocarboxylic acid and malathion dicarboxylic acid for malathion, and 2-isopropyl- 
4-methyl-6-hydroxypyrimidine (IMPY) for diazinon [20,21]. The metabolite 4-
nitrophenol has been used for estimating exposure to methyl and ethyl parathion but 
it is also a metabolite of EPN (O-ethyl O-(4-nitrophenyl) P-phenylphosphonothioate) 
and other non-organophosphate chemicals [20]. 
 
A metabolite of carbaryl, 1-naphthol has been measured to estimate exposure to this 
commonly used carbamate [20]. For pyrethroid insecticides, 3- phenoxybenzoic acid 
(3PBA) is a non-specific metabolite, common to about 20 synthetic pyrethroids. 
There are other more specific metabolites of pyrethroids that have been measured, 
including 4-fluoro-3-phenoxybenzoic acid (4F3PBA), a metabolite of cyfluthrin; cis-
2,2-dibromovinyl-2,2-dimethylcyclopropane-1-carboxylic acid (DBCA), a metabolite of 
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deltamethrin; and cis- and trans isomers of 2,2-dichlorovinyl-2,2- 
dimethylcyclopropane-1-carboxylic acid (cis- and trans-DCCA) which are metabolites 
of permethrin, cypermethrin and cyfluthrin [20].   
 
5. PATHOPHYSIOLOGICAL MECHANISMS 
 
5.1 Cytokine pathways in asthma 
 
Over the past few years, allergic airway inflammation that occurs in asthmatic 
individuals has been classified as being either eosinophilic or non-eosinophilic. It is 
widely accepted that eosinophilic airway inflammation is driven by the Th2 response 
[30], particularly so in mild and moderate asthma. However, the inflammatory 
response seen in severe asthma is complex as the Th1 response is also involved 
[30,31]. Th2 response produces several cytokines including IL-3, IL-4, IL-5, IL-9, IL-
10, IL-13 and IL-33 [30,31]; however, the major Th2 cytokines are IL-4, IL-5 and IL-
13. The cytokine IL-4 is thought to be very crucial during early stages of the allergic 
response (primary sensitisation) since it enhances the differentiation and stimulation 
of Th2 cells and production of IgE from the B cells. The cytokine IL-13 is considered 
to play a major role during secondary allergen exposure as it promotes mucus 
secretion, smooth muscle contraction and airway hyperresponsiveness. Like most 
other Th2 cytokines, IL-5 promotes eosinophil recruitment, differentiation and 
activation [30]. The predominant functions of different cytokines are summarised in 
Table 2. Various cytokines associated with different pathophysiological features of 
asthma are summarised in Table 3. 
 
5.2 Pesticides and asthma 
 
Many pesticides are irritants and can induce or aggravate existing asthma through 
their interaction with functional irritant receptors in the airways thereby inducing 
neurogenic inflammation [4]. On the other hand, if corrosive, pesticides can also 
cause direct damage to the airways [4].  
 
Mechanisms by which pesticides act as irritants is explained in detail in a recently 
published review article [4]. In summary, pesticides like other irritants can activate 
transient receptor potential (TRP) receptors located in the neuronal cells (sensory C-
fibers) and other cells including respiratory epithelia and inflammatory cells leading to 
the release of inflammatory neuropeptides thereby triggering neurogenic 
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inflammation [4]. An airway neurogenic inflammation is characterized by 
bronchoconstriction, increased mucus secretion and oedema which are typical 
features of asthma [4]. Nonspecific bronchial hyper-responsiveness and 
consequently asthma symptoms will manifest if this airway inflammation is sustained 
over time [4]. 
 
It has been proposed that organophosphate and carbamate insecticides induce 
asthma through inhibition of acetylcholinesterase [3]. However, chlorpyrifos (an 
organophosphate) has been found to cause airway hyperreactivity in guinea pigs 
through inhibition of the parasympathetic prejunctional muscarinic M2 receptor 
function at doses below those known to cause acetylcholinesterase inhibition [22]. 
Inhibition of M2 receptor function can also cause increased mucus secretion [4]. In 
another animal study, parathion and diazinon (organophosphates) also caused 
airway hyperreactivity through M2 receptor dysfunction without acetylcholinesterase 
inhibition [23]. The exact mechanism through which organophosphates decrease M2 
receptor function in the airway nerves is unknown. A recent study has suggested that 
the organophosphate inhibition of M2 receptor function is neither through direct 
pharmacologic antagonism nor through down regulation of M2 receptor expression 
[24]. 
 
Some pesticides can modulate inflammatory response to common allergens, for 
instance carbaryl has been found to enhance allergic responses to house dust mites 
in an animal study[25]. Some pesticides may modulate macrophage function. In 
animal studies, oral administration of malathion resulted in an increased macrophage 
function in mice, which was postulated to be due to the release of inflammatory 
mediators (arachidonic acid metabolites and tumour necrosis factor) from mast cells 
[26]. Interestingly, some pesticides may modulate allergic potentials of other 
pesticides [27]. The allergic potential of phenoxyacetic acid herbicide 2,4-D-butyl and 
a fungicide, eugenol were increased in mice exposed to parathion and methoxychlor 
[27]. Eugenol and 2,4-D-butyl are known to be contact allergens. These mice were 
found to have increased surface antigen expression of T cells and higher numbers of 
Th1 cytokines (interferon-IFN-γ and tumour necrosis factor-α) and interleukin (IL)-17 
[27]. 
 
Individuals sensitized to common allergens may be more susceptible to the effects of 
pesticides. This has also been shown in animal studies, in which guinea pigs 
sensitized to ovalbumin demonstrated a decreased threshold to parathion-induced 
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airway hyperreactivity [28]. Moreover, parathion effects on vagally induced 
bronchoconstriction were exacerbated in these sensitized guinea pigs [28]. 
Interestingly, sensitization also changed the mechanism of parathion-induced 
hyperreactivity from IL-5 independent to IL-5 dependent [28]. 
 
Some pesticides such as a carbamate, carbaryl; a fungicide, zineb; and the three 
herbicides: simazine, alachlor and nitrofen are endocrine disrupters [29]. Endocrine 
disrupters (EDs) are chemicals that not only interfere with the balance of endocrine 
system but also influence immune system [29]. Some evidence exists from animal 
data that demonstrate how EDs can enhance the allergic response. Laboratory 
studies have demonstrated that some EDs can enhance T helper cells 2 (Th2) 
development and thereby shifting T helper cells 1 (Th1) / Th2 balance towards that 
favouring the Th2 pathway. Th2 response produces Th2 cytokines such as IL-4, 5 
and 13, consequently leading to increased production of immunoglobulin E (IgE) [29].  
 
 
 
Table 2: Predominant functions of interleukins [modified from [31]] 
 
Cytokines Predominant function(s) 
IL-2 Eosinophilic recruitment, activation and inflammation 
IL-3 Eosinophilic recruitment, activation and inflammation 
IL-4 Eosinophilic recruitment, activation and inflammation 
IL-5 Eosinophilic recruitment, activation and inflammation 
IL-6 Pro- and anti-inflammatory 
IL-8 Neutrophil recruitment 
IL-9 Eosinophilic recruitment, activation and inflammation 
IL-10 Immunomodulation, anti-inflammatory 
IL-13 Eosinophilic recruitment, proinflammatory 
IL-17 Proinflammatory  
IL-33 Eosinophil recruitment, proinflammatory 
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Table 3: Cytokines associated with pathophysiological features of 
asthma [modified from [31]] 
 
Aspects of asthma  Interleukins  
Airway hyperresponsiveness  IL-2, IL-4, IL-5, IL-9, IL-13, IL-18, IL-33, TNF-α 
IgE production  IL-4, IL-9, IL-13, IL-18 
Goblet cell metaplasia  IL-4, IL-13 
Mucin hypersecretion  IL-9 
Mastocytosis IL-9 
Mast cell degranulation/migration  IL-9, IL-33 
Eosinophilia  IL-4, IL-5, IL-9, IL-13, IL-17, TNF- α 
Neutrophilia  IL-1, IL-2, IL-18, IL-33, TNF-α, IFN-γ 
Th2 induction  IL-4, IL-5, IL-9, IL-13, IL-25, IL-33 
Airway smooth muscle hypertrophy  IL-13, IL-33 
Remodelling epithelial damage/repair  IL-5, IL-9, IL-18, IL-33 
Subepithelial fibrosis  IL-13, IL-33 
Exacerbations  IL-4, IL-5, IL-6, IL-8, TNF-α 
 
 
6. CONCLUSION 
 
Several epidemiological studies have demonstrated associations between various 
specific pesticides and respiratory health outcomes including asthma and rhinitis, 
some of these showing evidence suggestive of possible dose-response relationships, 
but the methods for estimating exposures are generally crude and reliant on self-
reported exposures rather than objective markers for individual pesticides implicated.  
Future biological monitoring studies should therefore use standardized units of 
measurement in order to allow for easier comparison of different levels of pesticide 
residues between studies. 
 
Furthermore, since the pathophysiological mechanisms of asthma associated with 
exposure to pesticides is heterogeneous and not clearly understood; more studies 
are needed, particularly at the molecular level, in order to better understand the 
mechanisms involved. This will enable the development of improved approaches for 
exposure monitoring and medical surveillance of workers at increased risk of asthma 
and rhinitis associated with pesticides. 
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Part C: Publication-ready manuscript 
 
This manuscript has been prepared to be submitted for publication in the Journal, 
International Archives of Allergy and Immunology. The format of the article follows 
the journal’s guidelines for authors (Appendix G) except for the tables which are 
included in the main text and authors are not mentioned. 
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Abstract  
 
Background: A previous sub-study reported an association between allergic airway 
inflammation as determined by fractional exhaled nitric oxide (FeNO) and low levels 
of whole blood cholinesterase. This current study investigated the relationship 
between pesticide exposure (urinary pesticide metabolites) and asthma phenotypes 
(based on respiratory symptoms, cytokine patterns and exhaled nitric oxide profiles) 
among these women.  
 
Methods: A cross-sectional study was conducted among rural women working and 
living on the farms (farm dwellers, n=121) and those residing in the neighbouring 
towns (town dwellers, n=90). Pesticide exposure was assessed based on urinary 
metabolite concentrations of organophosphate (OP) and pyrethroid (PYR) residues. 
Health outcome assessment was ascertained through modified European 
Community Respiratory Health Survey questionnaire, FeNO concentrations, serum 
cytokine (Th2 and non-Th2 markers) concentrations, and immunological markers for 
atopy (Phadiatop) and specific IgE to house dust mite, storage mite and spider mite. 
  
Results: The median age of the study participants was 37 years (interquartile range: 
28 - 45 years). The urinary concentration (median and interquartile range) of OP 
metabolites (sum of the 6 dialkyl phosphate metabolites) = 134 (42-229) µg/g of 
creatinine; 3,5,6-trichloropyridinol (TCPY) = 5 (3-10) µg/g of creatinine; and for PYR 
(sum of the 5 PYR metabolites) = 6 (3-10) µg/g of creatinine. The prevalence of 
current asthma (asthma attack in the last 12 months or currently taking asthma 
medication) was 6%; doctor diagnosed asthma was 11%; and adult-onset asthma 
(history of doctor-diagnosed asthma and first asthma attack at age 16 years or older) 
was 9%. The proportion of subjects with FeNO above 50 ppb was 7% and between 
25-50 ppb was 11%. The proportion of Th2 cytokines (IL-4, IL-5 and IL-13) detected 
ranged from 18% to 40% while non-Th2 cytokines (IL-6, IL-8, IL-10, IL-17 and 
interferon-γ) ranged from 35% to 71%. IL-8 was the most commonly detected (71%) 
cytokine while IL-5 was the least detected (18%). Most OP metabolites were 
positively associated with FeNO levels above 50ppb. Both Th2 and non-Th2 
cytokines were positively associated with either OP or PYR metabolites. Non-Th2 
cytokines showed stronger associations with OP metabolites (the strongest 
association between diethyl dithiophosphate (DEDTP) and interferon-γ: prevalence 
odds ratio (95% confidence interval) = 25 (8-78)). 
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Conclusion: OP and PYR urinary metabolite levels in rural women in the Western 
Cape are higher than in the general population. This study provides evidence 
suggesting that both OP and PYR pesticides are associated with asthma, which may 
be due to Th2 and non-Th2 mechanisms, the latter pathway demonstrating 
consistently stronger relationships.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
49 
 
 
1. Introduction  
 
Pesticides are substances used extensively worldwide to kill or control certain forms 
of unwanted animal or plant life. Pesticides are widely used in agriculture and in 
several other settings including households, schools, leisure areas and also in the 
transportation facilities such as aeroplanes and boats [1,2].  Since pesticides are 
extensively used in the agricultural sector and a significant number of economically 
active South African population is employed in this sector, pesticides pose a 
significant public health problem. 
 
Despite their useful effects, pesticides have been associated with various health 
effects including adverse respiratory health outcomes such as asthma, rhinitis and 
non-specific respiratory symptoms [3]. In summary, the following specific pesticides 
have been associated with various adverse respiratory health outcomes including 
asthma: OP insecticides: diazinon, parathion, coumaphos, phorate, malathion, 
chlorpyrifos, terbufos, dichlorvos and fonofos; carbamate insecticide, carbaryl; 
organochlorine insecticides: chlordane, heptachlor, lindane and DDT 
(dichlorodiphenyltrichloroethane); PYR insecticide, permethrin; herbicides: 2,4,5-TP 
(2,4,5-trichlorophenoxypropionic acid), paraquat, diquat, EPTC (ethyl 
dipropylthiocarbamate), 2,4-D (2,4-dichlorophenoxyacetic acid), glyphosate, atrazine, 
chlorimuron-ethyl, imazethapyr, metolachlor, metribuzin, pendimethalin, petroleum 
oil, alachlor and trifluralin; fungicides: captan, metalaxyl and benomyl; and fumigants: 
ethylene dibromide and 80/20 mix [4–11]. A few other studies have demonstrated the 
association between different adverse respiratory health outcomes and the exposure 
to broad groups of pesticides but the specific pesticides were not identified [12–16].  
 
The pathophysiological mechanism of asthma associated with exposure to pesticides 
is heterogeneous and not clearly understood. More studies are needed, particularly 
at the molecular level to better understand the mechanisms involved. Furthermore, 
the methods for estimating exposures used in previous studies have been generally 
crude and reliant on self-reported exposures highlighting the need for more objective 
markers for individual pesticides. 
 
Traditionally, acetylcholinesterase measurements in blood have been used as a 
proxy for estimating exposure to OP and carbamate insecticides. With increasing 
laboratory analytical capabilities, several pesticide metabolites, commonly measured 
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in the urine samples, have also been used to estimate exposure to pesticides. The 
most commonly measured metabolites for estimating exposure to OPs are the six 
dialkyl phosphate (DAP) metabolites [dimethyl phosphate (DMP), diethyl phosphate 
(DEP), dimethyl thiophosphate (DMTP), dimethyl dithiophosphate (DMDTP), diethyl 
thiophosphate (DETP) and diethyl dithiophosphate (DEDTP)] [17]. These DAP 
metabolites are non-specific, in that they reflect short-term exposure to OPs but are 
not able to identify a specific OP. The metabolite 3,5,6- trichloropyridinol (TCPY), on 
the other hand is a specific metabolite frequently measured for estimating exposure 
to a commonly used OP, chlorpyrifos [17–19]. Other less commonly measured 
specific OP metabolites include α and β isomers of malathion monocarboxylic acid 
and malathion dicarboxylic acid for malathion and 2-isopropyl- 4-methyl-6-
hydroxypyrimidine (IMPY) for diazinon [18,20]. The metabolite 4-nitrophenol has 
been used for estimating exposure to methyl and ethyl parathion but it is also a 
metabolite of EPN (O-ethyl O-(4-nitrophenyl) P-phenylphosphonothioate) and other 
non-organophosphate chemicals [18]. 
 
For PYR insecticides, 3- phenoxybenzoic acid (3PBA) is a non-specific metabolite, 
common to about 20 synthetic pyrethroids. There re other more specific metabolites 
of pyrethroids that have been measured, including 4-fluoro-3-phenoxybenzoic acid 
(4F3PBA), a metabolite of cyfluthrin; cis-2,2-dibromovinyl-2,2-dimethylcyclopropane-
1-carboxylic acid (DBCA), a metabolite of deltamethrin; and cis- and trans isomers of 
2,2-dichlorovinyl-2,2- dimethylcyclopropane-1-carboxylic acid (cis- and trans-DCCA) 
which are metabolites of permethrin, cypermethrin and cyfluthrin [18]. 
 
Over the past few years, allergic airway inflammation that occurs in asthmatic 
individuals has been classified as being either eosinophilic or non-eosinophilic. It is 
widely accepted that eosinophilic airway inflammation is driven by the Th2 response 
[21], particularly so in mild and moderate asthma. However, the inflammatory 
response seen in severe asthma is complex as the Th1 response is also involved 
[21,22]. Th2 response produces several cytokines including interleukins (IL) -3, IL-4, 
IL-5, IL-9, IL-10, IL-13 and IL-33 [21,22]; however, the major Th2 cytokines are IL-4, 
IL-5 and IL-13. The cytokine IL-4 is thought to be very crucial during early stages of 
the allergic response (primary sensitisation); it enhances the differentiation and 
stimulation of Th2 cells and production of IgE from the B cells. The cytokine IL-13 is 
considered to play a major role during secondary allergen exposure as it promotes 
mucus secretion, smooth muscle contraction and airway hyperresponsiveness. Like 
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most other Th2 cytokines, IL-5 promotes eosinophil recruitment, differentiation and 
activation [21]. 
 
This analysis is part of a larger study investigating various health effects of pesticide 
exposure among rural women in the Western Cape Province in South Africa. In a 
previous sub-study [3], women having FeNO levels greater than 50 ppb had an 
almost 5 fold increased odds (OR = 4.80; 95% CI: 0.80 - 28.00) of cholinesterase 
(ChE) levels below the laboratory reference standard (6021 IU, Roche Diagnostics®) 
when compared to women with ChE levels above this reference value. This finding 
suggested a probable association between exposure to ChE depressing pesticides 
(organophosphate and carbamate insect ides) and allergic asthma. This current 
study was conducted to determine urinary levels of OP and PYR pesticide 
metabolites; to examine cytokine pathways among individuals exposed to pesticides; 
and finally to assess the association between exposure to these pesticides and 
various asthma phenotypes.  
 
2. Materials and Methods 
 
2.1. Study design, population and sampling 
 
A cross-sectional study of women farm workers and residents living in towns 
neighbouring the farms, in the Western Cape Province of South Africa was 
conducted during the period 24 October to 3 December 2009. The recruitment of 
study participants was accomplished with the assistance of a non-governmental 
organisation, Women on farms (WFP). The farm areas included Stellenbosch, Ceres, 
Paarl, Grabouw and Worcester. Farm workers and residents were selected from the 
5-10 most accessible but representative farms in each area and town dwellers from 
the most accessible and representative houses in each area. One adult female 
participant per household was selected. A total of 211 women were recruited into the 
study including 113 women currently living on a farm and 98 in towns. Eight women 
lived in the town but worked on a farm, these were included in the farm worker group. 
There were a total of 97 farm workers (89 women living in farms and 8 not living in 
farms). There were 24 women residing but not working on farms. The farm workers 
and residents (n = 121) are referred to as “farm dwellers”. There were 90 women 
who neither lived nor worked on a farm and they are referred to as “town dwellers”.  
The study was conducted in accordance with the Declaration of Helsinki (23). The 
study was approved by the University of Cape Town’s Human Research Ethics 
Committee (Reference 393/2009) (Appendix D and E).  
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2.2. Questionnaire 
 
The questionnaire  had sections on socio-demographic aspects (age, schooling, 
home language, income, employment);  residential history (place of residence on a 
farm or town, period of residence); environmental pesticide exposure (pesticide drift, 
distance of residence to spraying and other exposures to agricultural spraying); job 
history (farm worker, non-farm worker, number of years in a job, job title); household 
pesticide exposure; lifestyle factors (smoking and alcohol consumption) and 
respiratory health. The respiratory health section incorporated the abbreviated form 
of the standardised and validated European Community Respiratory Health Survey 
questionnaire [24]. The non-respiratory questions in the questionnaire were based on 
those used in previous surveys conducted in South Africa [4,25]. The questionnaire 
was translated into Afrikaans and Xhosa and thereafter back translated to ensure 
accuracy of the translation. Trained interviewers administered questionnaires to 
participants in the language of their choice.  
 
2.3. Urinary pesticide metabolites determination 
 
Spot urinary samples (50 ml) were collected in plastic containers topped with a 
plastic cap and kept on dry ice in the field and during transport and then stored at -20 
degrees Celsius before being sent to the laboratory for analysis.  The urine samples 
were couriered to National Institute for Occupational Health (NIOH) laboratory in 
Johannesburg which conducted the analyses for organophosphate pesticide 
metabolites, dialkyl phosphates, the chlorpyrifos metabolite, TCPY and the pyrethroid 
metabolites. 
 
An insecticide screen that employs a high performance liquid 
chromatography/tandem mass spectrometry-based method and quantification using 
the isotope dilution (ID) calibration [26] was used to screen urine for 
organophosphate and pyrethroid insecticides.  Briefly, using ID calibration, the 
samples were enriched with isotopically labelled analogues prior to preparation.  
Chemically the isotope analogue behaves identically to the native analyte, but can be 
discriminated with a mass filter [27].  This allows complete recovery correction for 
each sample and improves the sensitivity, accuracy, and selectivity of the analysis.  
After addition of the labelled standard to urine samples, glucuronide or sulfate-bound 
urinary metabolites were liberated by enzyme hydrolysis and the analytes were 
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isolated using solid phase extraction.  The extractants were concentrated to dryness 
and reconstituted in solvent for analysis by ID-high performance liquid 
chromatography-atmospheric chemical ionization-tandem mass spectrometric 
(MS/MS).  Five PYR metabolites (3PBA, 4F3PBA, DBCA, cis-DCCA and trans-
DCCA) and seven OP metabolites (TCPY and the six DAP metabolites (DMP, DEP, 
DMTP, DMDTP, DETP and DEDTP)) were screened.  Results were adjusted for 
concentration by creatinine. The limit of detection (LOD) for the pesticide metabolites 
were 0.5 µg/l for TCPY; 1 µg/l for DMP; and 0.05 µg/l for DMTP, DMDTP, DEP, 
DETP, DEDTP, cis-DCCA, trans-DCCA, DBCA, 4F3PBA and 2PBA .    
 
2.4. Serum cytokines determination 
 
All blood samples were collected during the afternoon and early evening to 
accommodate those who were working during the day. A blood sample (9 ml) was 
drawn from each participant using a Becton Dickinson Vacutainer SST tube (with gel 
medium and clot activator) by the qualified nurse. The blood was allowed to clot for 
1-2 hours at room temperature (20-24 degrees Celsius) and then centrifuged at 
1350g for 10 minutes at room temperature. The serum was then transferred to 
another tube and stored at -20 degrees Celsius in a field freezer. The stored serum 
sample was transported on dry ice to the School of Public Health and Family 
Medicine, UCT where it was stored at -80 degrees Celsius until assayed for further 
measurement. The samples were couriered to the NIOH Immunology laboratory for 
testing. Some part of the serum was used for other immunology tests in the original 
study (sensitisation to house dust mite, storage mite and spider mite). The remaining 
amount of serum was used for cytokine analysis. The BDTM CBA Human 
Inflammation kit was used to quantitatively measure non-allergic inflammatory 
interleukin (IL-8, IL-6, IL-10, IL-17, interferon gamma) protein levels in each serum 
sample.  Six bead populations with distinct fluorescence intensities coated with the 
specific interleukins were multiplexed and resolved in the red channel of the flow 
cytometer (BD FacsArrayTM) (Becton Dickson, Oxford, UK).  
 
The inflammatory interleukins associated with allergy (IL-4, IL-5, IL-13) were 
measured using the BDTM CBA Human Soluble Protein Flex Set assay according to 
the manufacturer’s instructions. The assay allow for multiplexed analysis of multiple 
proteins from a single sample.  The concentrations were determined using the 
(FacsArrayTM) (Becton Dickson, Oxford, UK). 
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Standard curves of the standard serial dilutions, expressed by a 4 parameter logistic 
model (log CC = D + (A – D) / (1 + (log I / C)^B) (where A=minimum asymptote, 
B=slope factor, C=inflection point, D=maximum asymptote), were used to determine 
the limit of detection (LOD) for each specific analyte (IL-4, IL-5, IL-6, IL-8, IL-10, IL-
13, IL-17, IFN-γ) based on the average median fluorescent intensity (MFI) of the 
negative control. The concentration of analyte was expressed as picogram per 
millilitre (pg/ml). A regression coefficient (R2) for the standard curve for each analyte 
was accepted if ≥ 0.98. The assay detection limit for each analyte was determined by 
the average fitted concentration of the negative control (0 pg/ml) + 2 standard 
deviations for each analyte.  The LOD for each cytokine were 0.10 pg/ml for IL-4, IL-
5, IL-8, IL-13 and IFN-γ; 0.14 pg/ml for IL-6; 0.20 pg/ml for IL-10 and 0.22 pg/ml for 
IL-17 (Table 3).  
 
2.5. Fractional exhaled nitric oxide (FeNO determination 
 
Fractional exhaled nitric oxide measurement is a recognised non-invasive method for 
the assessment of allergic airway inflammation [28,29]. Under the guidance of an 
experienced nurse FeNO levels were determined from single-breath exhalations. The 
technique involved inspiration of nitric oxide (NO)-free air via a mouthpiece to total 
lung capacity, followed immediately by full exhalation at an even rate through the 
mouthpiece into the apparatus. A hand-held portable nitric oxide sampling device 
(NIOX MINO® Airway Inflammation Monitor (NIOX MINO); Aerocrine AB, Solna, 
Sweden) was used. Three technically adequate measurements were performed in 
line with the current American Thoracic Society /European Respiratory Society 
recommendations [30]. The FeNO test was done after hours during the working 
week. Special instructions were provided to workers to ensure that tested individuals 
do not smoke tobacco, eat or drink (at least 1 hour before) prior to the test. The 
participants’ height and weight were measured and this information was used to 
calculate BMI. Ambient NO and temperature were also recorded. 
 
2.6. Statistical analysis 
 
The exposure variables of interest were the urinary levels of OP metabolites 
including diakyl phosphates (DMP, DEP, DMTP, DMDTP, DETP and DEDTP) and 
TCPY and PYR metabolites (3PBA; 4F3PBA; DBCA and cis-DCCA and trans-
DCCA). Two additional variables included the sum of all 6 DAP metabolites and the 
sum of all 5 pyrethroid metabolites. These metabolites levels were also dichotomised 
as above the 75th percentile of the detected values. 
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The main outcome variables defined were doctor-diagnosed asthma, adult-onset 
asthma, current asthma, FeNO levels between 25 and 50ppb, FeNO levels above 
50ppb and the cytokine levels detected. Adult-onset asthma was defined as history of 
doctor-diagnosed asthma and having had the first asthma attack at the age of 16 
years or later. Current asthma was defined as having had an attack of asthma in the 
last 12 months or currently taking medicines for asthma. Cytokine levels were 
dichotomised as individually detected and non-detected as well as any Th2 or non-
Th2 detected in serum. 
 
The data was analysed using Stata statistical package version 12 [31]. Frequency 
distributions, Chi-square test and simple logistic regressions were used to assess the 
association between categorical variables. Continuous variables were summarised 
using median and interquartile range since they were not normally distributed. 
Wilcoxon sum rank test was used to assess the association between binary variables 
and continuous variables.  Multivariate regression analyses were used to examine 
the association between the outcomes of interest and pesticide metabolites 
controlling for confounders. Confounders selected to be included in the models were 
current smoking, atopy, born on a farm, and level of education as demonstrated in 
the previous sub-study [3].  
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3. Results 
 
3.1. Demographic characteristics, allergic and asthma outcomes (n=211) 
 
The demographic characteristics and the prevalence of asthma and allergic 
outcomes are presented in Table 1. Town dwellers were significantly older and with 
significantly higher body mass index (BMI) than farm dwellers. Level of education 
was generally low in both town and farm dwellers. 
    
Overall, half of the study population were current smokers with a higher proportion 
(57%) being among farm dwellers (Table 1). The majority of farm dwellers were 
employed unlike the town dwellers. A large proportion (69%) of women who were 
born on a farm were still living and working on a farm although a minority (14%) of 
town dwellers reported being born on a farm. 
 
Town dwellers had on average significantly higher FeNO levels compared to farm 
dwellers (Table 1). Almost half (44%) of the study population were atopic. 
Interestingly, the prevalence of all asthma and allergic outcomes was higher among 
town dwellers, although this did not reach statistical significance. The levels of IgE to 
storage mite and spider mite were not significantly different between farm and town 
dwellers. 
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Table 1: Demographic characteristics, allergic and asthma outcomes among 
rural women in the Western Cape (n=211) 
 
Characteristics  Farm dwellers  
(n = 121)  
Town dwellers  
(n = 90)  
Overall  
(n = 211)  
Demographic characteristics:  (median, interquartile range)  
Age (years)  33(27-40)***  40.5(31-49)  37(28-45)  
BMI (kg/m2) 25.18(21.57-30.81)**  28.58(23.78-35.71)  26.44(22.52-32.87)  
Education (years of schooling)  9(7-10)  9 (7-11)  9(7-10)  
Length of stay in current residence (years)  15(8-24)**  22(12-41)  17(9-29)  
Born on a farm:  n (%) 83 (69)***  13 (14)  96 (46)  
Current smoker:  n (%) 69 (57)*  36 (40)  105 (50)  
Currently employed:  n (%) 101 (84)***  25 (28)  126 (60)  
Asthma phenotypes: n (%) 
Asthma attack in the last 12 months 2 (2) 1 (1) 3 (1) 
Currently taking medicines for asthma 4 (3) 8 (9) 12 (6) 
Current asthma 4 (3) 8 (9) 12 (6) 
Doctor-diagnosed asthma 11 (9) 12 (13) 23 (11) 
Adult-onset asthma 9 (7) 10 (11) 19 (9) 
FeNO (ppb): median (interquartile range) 9.17(5.67-14)** 12.33(8.33-22.33) 10.33(6-17.33) 
FeNO=25ppb-50ppb 11 (9) 12 (14) 23 (11) 
FeNO>50ppb 7 (6) 8 (9) 15 (7) 
Allergic sensitisation: n (%) 
Atopy (positive Phadiatop) 46 (38) 44 (51) 90 (44) 
Storage mite sensitisation  
(Lepidoglyphus destructor) 
23 (19) 21 (24) 44 (21) 
Spider mite sensitisation  
(Tetranychus urticae) 
18 (15) 17 (20) 35 (17) 
*p < 0.05; **p < 0.01; ***p < 0.001; BMI: body mass index 
Current smoker: having smoked at least 20 packs of cigarettes or 30 grams of tobacco in a lifetime or at least one 
cigarette per day for one year AND having smoked tobacco in the last month or more 
Current asthma: asthma attack in the last 12 months or currently taking medicines for asthma; 
Adult-onset asthma: history of doctor-diagnosed asthma and having had the first asthma attack at the age of 16 
years or later 
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3.2. Urinary pesticide metabolite concentrations 
 
Table 2 summarises the results of the urinary pesticide metabolites (adjusted for 
creatinine) detected in the study population. The descriptive statistics presented in 
Table 2 are only for the detected values. However, when the data for the values 
below LOD were transformed to the LOD divided by the square root of 2 and the 
descriptive statistics recalculated (Supplementary Table 1), the median and 
interquartile range did not change significantly from those estimated using the former 
method. Urine samples from 18 participants were outside the WHO recommended 
creatinine concentration range of 0.3 × 106µg/L – 3.0 × 106µg/L [32]. For some 
participants, urine samples were not sufficient to measure concentrations of the 
pesticide metabolites (7 for TCPY, 15 for dialkyl phosphates and 10 for pyrethroid 
metabolites). Only 10 individuals had undetected levels of pesticide metabolites (8 for 
TCPY, one for DMTP and one individual for all the pyrethroid metabolites). Pesticide 
metabolites measured were detected in the majority of samples in both farm and 
town dwellers. Most of the pesticide metabolites detected were higher among farm 
dwellers (range of difference: 0.03 to 6.72 µg/g of creatinine) except for the DMTP, 
DMDTP and DETP which were in contrast higher among town dwellers (Table 2). 
TCPY and trans-DCCA were statistically significantly higher among farm dwellers. 
DMP and DMTP were the predominant organophosphate metabolites detected while 
3PBA was the predominant pyrethroid metabolite detected. 
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Table 2: Urinary pesticide metabolites levels detected among rural women in 
the Western Cape 
 
Pesticide 
metabolites 
Farm dwellers Town dwellers Overall 
Median (interquartile range) 
Corrected for creatinine (µg/g creatinine) 
I. Organophosphate metabolites 
          Dialkyl phosphates (n = 178) 
∑DAP 141.42(37.4-249.83)  132(45.64-204.45) 133.59(41.86-229.09) 
   DMP   32.91(13.50-55.75)   26.19(14.33-52.36)   29.63(14.06-53.22) 
   DMTP (n=177)   13.41(3.05-62.45)   37.86(6.55-77.20)   22.04(4.53-65.85) 
   DMDTP     5.70(0.83-51.51)     9.57(0.87-66.22)     6.87(0.85-61.77) 
   DEP     5.01(1.37-12.90)     4.13(0.59-9.47)     4.27(1.08-10.04) 
   DETP     3.70(1.15-26.98)     3.94(1.35-26.18)     3.87(1.20-26.98) 
   DEDTP     1.99(0.55-5.10)     1.70(0.60-8.02)     1.89(0.58-6.44) 
          Chlorpyrifos metabolite (n = 178) 
TCPY     6.35(3.67-10.95)*     4.26(2.72-8.27)     5.38(3.25-9.45) 
II. Pyrethroid metabolites (n = 182) 
Pyrethroids     6.60(3.61-9.96)     5.26(2.74-8.42)     6.01(3.24-9.67) 
   cis-DCCA     0.72(0.27-1.28)     0.56(0.23-1.13)     0.63(0.26-1.24) 
   trans-DCCA     0.85(0.48-1.29)**     0.59(0.28-1.02)     0.70(0.37-1.22) 
   DBCA     0.33(0.05-0.63)     0.30(0.04-0.60)     0.31(0.05-0.62) 
   4F3PBA     0.76(0.35-1.32)     0.70(0.33-1.30)     0.73(0.33-1.32) 
   3PBA     3.85(2.13-6.25)     3.34(2.27-5.92)     3.41(2.21-6.00) 
*p < 0.05; **p < 0.01; TCPY: 3,5,6- trichloropyridinol; ∑DAP: sum of the 6 dialkyl phosphate metabolites; DMP: 
dimethyl phosphate 
DMTP: dimethyl thiophosphate; DMDTP: dimethyl dithiophosphate; DEP: diethyl phosphate; DETP: diethyl 
thiophosphate 
DEDTP: diethyl dithiophosphate; Pyrethroids: sum of the 5 pyrethroid metabolites;  
cis-DCCA: cis- 2,2-dichlorovinyl-2,2- dimethylcyclopropane-1-carboxylic acid 
trans-DCCA: trans- 2,2-dichlorovinyl-2,2- dimethylcyclopropane-1-carboxylic acid 
DBCA: cis-2,2-dibromovinyl-2,2-dimethylcyclopropane-1-carboxylic acid; 
4F3PBA: 4-fluoro-3-phenoxybenzoic acid; 3PBA: 3- phenoxybenzoic acid 
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3.3. Serum cytokine concentrations (n=201) 
 
Table 3 summarises the results of the cytokine concentrations measured and the 
proportion of each cytokine detected. Cytokine data were available for 201 out of 211 
participants. Blood samples could not be obtained from 5 participants and for another 
5 participants their serum samples were insufficient for analysis. Th2 cytokine levels 
were on average higher among town dwellers with IL-13 reaching a statistically 
significant higher level (p<0.05) in this group. There was no consistent pattern among 
non-Th2 cytokines with some (IL-6 and IL-8) being higher among town dwellers while 
others (IL-10, IL-17 and IFN- γ) being higher among farm dwellers. The proportion of 
Th2 cytokines detected ranged from 18% to 40% while non-Th2 cytokines ranged 
from 35% to 71%. The proportion of cytokines detected was not significantly different 
between town and farm dwellers but, in general, IL-8 was the most dominantly 
detected (71%) cytokine while IL-5 was the least detected (18%). 
 
3.4. Host and other potential confounders associated with asthma outcomes  
 
Table 4 summarises the unadjusted logistic regression models of the relationship 
between potential confounders and the asthma outcomes. Age, BMI, current 
employment and currently living in a farm were not associated with any asthma 
outcome. Atopy, current smoking, level of education and being born on a farm were 
associated with some asthma outcomes. None of the potential confounders was 
associated with the cytokines, notably atopy was not associated with Th2 cytokines. 
 
 
3.5. Association between pesticide metabolites and asthma outcomes using 
multiple regression models 
 
Table 5 and 6 summarise the results of adjusted multiple logistic regression models 
of the association between pesticide metabolites and different asthma phenotypes 
including cytokines. TCPY was weakly and positively associated with virtually all 
asthma, FENO and cytokine outcomes. Most organophosphate metabolites were 
associated with higher odds of FeNO levels above 50ppb, the strongest association 
being with DEP (OR = 2.54; 95% CI: 0.62 - 10.37). However, there was no consistent 
association between pesticide metabolites and other asthma outcomes. Both non-
Th2 and Th2 cytokines were positively associated with pesticide metabolites 
although non-Th2 cytokines especially IL-8 showed stronger associations with ethyl 
phosphate metabolites (DEP, DETP and DEDTP). There was no consistent 
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association between cytokine levels (continuous variables) and pesticide metabolites 
in multiple linear regression models (data not shown). 
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Table 3: Serum cytokine levels detected among rural women in the Western Cape 
  
Cytokines Distribution of detected values  
median (interquartile range) in pg/ml 
Limit of 
detection 
(pg/ml) 
Proportion detected 
n (%) 
Farm dwellers Town dwellers Overall Farm 
dwellers  
Town 
dwellers  
Overall  
 
Th2 cytokines    
IL-4 4.68(3.20-6.92) 5.09(3.52-8.12) 4.84(3.52-7.25) 0.10 51 (43) 30 (37)  81 (40) 
IL-5 2.06(1.66-2.31) 2.23(1.82-3.16) 2.07(1.68-2.60) 0.10 23 (19) 13 (16)  36 (18) 
IL-13 4.80(2.98-6.37)* 6.06(4.90-7.58) 5.55(3.39-7.23) 0.10 39 (33) 28 (34)  67 (33) 
Any Th2 N/A N/A 61 (51) 44 (54) 105 (52) 
Non-Th2 cytokines    
IL-6 5.16(3.61-7.50) 5.27(3.75-10.26) 5.16(3.62-8.69) 0.14 63 (53) 38 (46) 101 (50) 
IL-8 16.49(10.56-36.22) 19.47(13.08-37.30) 18.93(11.45-36.90) 0.10 85 (71) 57 (70) 142 (71) 
IL-10 4.47(2.80-5.60) 4.22(2.74-6.36) 4.39(2.77-5.87) 0.20 45 (38) 26 (32)  71 (35) 
IL-17 10.34(6.20-15.61) 9.13(7.09-19.02) 9.76(6.40-16.10) 0.22 52 (44) 28 (34)  80 (40) 
IFN-γ 10.53(7.41-17.80) 9.14(6.56-17.30) 10.30(7.41-17.30) 0.10 60 (50) 31 (38)  91 (45) 
Any non-Th2 N/A N/A 85 (71) 57 (70) 142 (71) 
IL: interleukin; IFN- γ: interferon gamma; * p-value<0.05; Any Th1: any of the Th1 cytokines (IL-6, IL-8, IL-17, IL-10 or IFN-γ); Any Th2: any of the Th2 cytokines (IL-4, IL-5 or IL-13) 
N/A: Not applicable 
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Table 4: Unadjusted logistic regression models of the association between potential confounders and asthma outcomes among rural 
women in Western Cape 
 
 
Asthma outcomes. Odds Ratio (95% Confidence Interval)  
 
Doctor 
diagnosed 
asthma  
Adult onset 
asthma  
Current asthma  FeNO=25ppb-
50ppb  
FeNO>50ppb  Any of non-Th2 
cytokines 
detected 
Any of Th2 
cytokines 
detected 
Prevalence, (%) 
(n=211)  
11%  9%  6%  11%  7%  71% 52% 
Age (years)  1.01(0.98-1.05)  1.02(0.99-1.06)  1.04(0.99-1.09)  1.00(0.95-1.03)  0.99(0.95-1.04)  1.00(0.97-1.02) 1.00(0.97-1.02) 
BMI (kg/m2)  1.02(0.96-1.08)  1.03(0.97-1.10)  1.01(0.93-1.10)  1.05(0.98-1.11)  1.02(0.95-1.10)  1.02(0.98-1.07) 1.01(1.00-1.05) 
Education (years of 
schooling)  
0.85(0.74-0.96)***  0.85(0.74-0.97)*  0.78(0.66-0.92)**  0.95(0.83-1.09)  1.18(0.96-1.46)  1.02(0.93-1.13) 0.98(0.89-1.07) 
Born on a farm  0.61(0.25-1.50)  0.67(0.25-1.79)  0.10(0.01-0.79)*  0.29(0.10-0.81)*  0.27(0.07-0.99)*  1.17(0.63-2.15) 1.07(0.62-1.87) 
Current smoker  1.66(0.68-4.02)  1.43(0.55-3.72)  1.44(0.44-4.70)  0.62(0.25-1.49)  0.23(0.06-0.84)*  0.77(0.42-1.41) 0.68(0.39-1.19) 
Currently employed  0.86(0.36-2.07)  0.73(0.28-1.87)  0.46(0.14-1.50)  0.56(0.24-1.34)  0.55(0.19-1.58)  1.36(0.74-2.53) 0.90(0.51-1.59) 
Atopy (Positive 
Phadiatop )  
3.37(1.32-8.58)*  3.10(1.13-8.5)*  7.12(1.52-33.40)*  2.20(0.90-5.34)  21.28(2.74-165.23)***  1.32(0.71- 2.45) 1.09(0.62-1.90) 
Farm vs. town 
dwellers 
0.65(0.27-1.55) 0.64(0.25-1.65) 0.35(0.10-1.20) 0.63(0.26-1.51) 0.61(0.21-1.76) 1.10(0.59-2.03) 0.91(0.52-1.60) 
*p < 0.05; **p < 0.01; ***p < 0.001; Each OR represents a separate unadjusted logistic regression model;  
Any Th1: any of the Th1 cytokines (IL-6, IL-8, IL-17, IL-10 or IFN-γ); Any Th2: any of the Th2 cytokines (IL-4, IL-5 or IL-13) 
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Table 5: Adjusted multiple logistic regression models of the association between pesticide metabolites and asthma outcomes among 
rural women in Western Cape 
 
Pesticide 
metabolites 
Asthma outcomes: Odds Ratio (95% Confidence Interval) 
Doctor-
diagnosed 
asthma 
Adult-onset 
asthma 
Current asthma FeNO: 25ppb–
50ppb 
FeNO > 50ppb Any non-Th2 
cytokine detected 
Any Th2 cytokine 
detected 
I. Organophosphate metabolites 
          Dialkyl phosphates  
∑DAP 0.68(0.23-2.05) 0.66(0.20-2.20) 1.38(0.33-5.76) 0.66(0.22-1.92) 2.53(0.74-8.64) 1.77(0.81-3.87) 1.77(0.90-3.46) 
  DMP 0.16(0.02-1.29) 0.22(0.03-1.72) 0.54(0.06-4.83) 0.17(0.02-1.33) 1.77(0.40-7.88) 4.23(1.54-11.65)** 1.69(0.83-3.46) 
  DMTP 0.12(0.02-0.94)* 0.16(0.02-1.29) ¥ 1.03(0.33-3.23) 0.47(0.10-2.15) 1.34(0.60-3.00) 0.85(0.42-1.72) 
  DMDTP 1.52(0.53-4.33) 1.91(0.62-5.82) 2.47(0.60-10.13) 1.78(0.60-5.29) 1.80(0.45-7.23) 0.46(0.22-0.98)* 0.79(0.39-1.62) 
  DEP 0.78(0.23-2.62) 1.08(0.31-3.71) 0.74(0.13-4.31) 1.26(0.40-3.97) 2.54(0.62-10.37) 2.71(1.05-7.00)* 1.99(0.95-4.19) 
  DETP 1.45(0.46-4.60) 2.03(0.61-6.73) 1.53(0.26-8.97) 0.65(0.17-2.49) 1.06(0.23-4.87) 23.25(3.08-175.49)** 2.75(1.27-5.92)* 
  DEDTP 1.19(0.38-3.78) 1.67(0.51-5.45) 0.77(0.13-4.51) 0.80(0.24-2.72) 0.97(0.22-4.33) 23.84(3.15-180.74)** 7.70(3.00-19.74)*** 
          Chlorpyrifos metabolite  
TCPY 1.35(0.47-3.92) 1.41(0.45-4.44) 1.26(0.27-5.76) 1.56(0.52-4.65) 1.50(0.35-6.38) 1.93(0.83-4.45) 1.56(0.57-2.34) 
II. Pyrethroid metabolites  
Pyrethroids 0.62(0.19-2.02) 0.84(0.26-2.77) 2.04(0.48-8.59) 0.13(0.02-0.98)* 0.35(0.07-1.90) 2.18(0.98-4.88) 1.32(0.69-2.55) 
  cis-DCCA 0.11(0.01-0.93)* 0.16(0.02-1.29) 0.23(0.02-2.62) 0.33(0.07-1.58) 0.59(0.10-3.53) 2.10(0.92-4.80) 1.47(0.73-2.93) 
  trans-DCCA 0.14(0.02-1.19) ¥ 0.28(0.02-3.47) 0.78(0.20-2.96) 0.81(0.12-5.31) 1.21(0.56-2.63) 1.04(0.52-2.10) 
  DBCA 0.17(0.02-1.30) 0.22(0.03-1.74) ¥ 0.97(0.29-3.29) 0.94(0.20-4.36) 1.74(0.78-3.88) 1.33(0.66-2.67) 
  4F3PBA 1.01(0.30-3.40) 1.40(0.40-4.90) 1.74(0.29-10.56) 0.69(0.18-2.62) 1.07(0.23-5.04) 4.32(1.58-11.82)** 2.51(1.20-5.22)* 
  3PBA 1.06(0.35-3.19) 1.15(0.35-3.76) 2.64(0.61-11.47) 0.14(0.02-1.10) 0.40(0.07-2.31) 1.63(0.72-3.69) 1.30(0.64-2.64) 
Adjusted for current smoking, atopy, born on a farm and level for education; Each OR represents a separate adjusted logistic regression model 
Pesticide residues categorized as above 75 percentile of the detected values; ¥ OR not calculable; Any Th1: any of the Th1 cytokines (IL-6, IL-8, IL-17, IL-10 or IFN-γ);  
Any Th2: any of the Th2 cytokines (IL-4, IL-5 or IL-13) 
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Table 6: Adjusted multiple logistic regression models of the association between pesticide metabolites and cytokines among rural 
women in Western Cape 
 
Adjusted for current smoking, atopy, born on a farm and level for education; Each OR represents a separate adjusted logistic regression model  
Pesticide residues categorized as above 75 percentile of the detected values; Cytokines categorised as detected vs. non-detected 
 
 
Pesticide 
metabolites 
  Cytokines: Odds Ratio (95% Confidence Interval)  
Th2 cytokines Non-Th2 cytokines 
IL-4 IL-5 IL-13 Il-6 IL-8 IL-10 IL-17 IFN-γ 
I. Organophosphate metabolites 
          Dialkyl phosphates  
∑DAP 1.60(0.83-3.11) 2.92(1.33-6.43)** 1.49(0.76-2.93) 1.77(0.91-3.44) 1.77(0.81-3.87) 1.83(0.93-3.60) 2.25(1.16-4.37)* 1.70(0.88-3.27) 
  DMP 2.34(1.14- 4.82)* 2.00(0.82-4.87) 1.38(0.65-2.92) 3.69(1.72-7.92)** 4.23(1.54-11.65)** 2.65(1.28-5.52)** 3.58(1.71-7.48)** 3.25(1.57-6.72)** 
  DMTP 1.59(0.77- 3.29) 0.84(0.31-2.31) 0.49(0.21-1.13) 1.76(0.86-3.61) 1.34(0.60-3.00) 1.06(0.50-2.26) 1.53(0.74-3.14) 0.85(0.42-1.73) 
  DMDTP 0.39(0.17-0.88)* 0.28(0.08-1.01) 1.39(0.66-2.94) 0.21(0.09-0.47)*** 0.46(0.22-0.98)* 0.27(0.11-0.71)** 0.25(0.10-0.59)** 0.39(0.18-0.83) 
  DEP 3.50(1.65-7.44)** 7.76(3.15-19.11)*** 1.87(0.89-3.95) 3.43(1.57-7.49)** 2.71(1.05-7.00)* 7.79(3.40-
17.83)*** 
4.59(2.13-9.89)*** 3.63(1.70-7.73)** 
  DETP 4.09(1.90-8.77)*** 8.15(3.27-20.30)*** 2.35(1.11-4.99)* 5.85(2.49-13.79)*** 23.25(3.08-
175.49)** 
4.18(1.95-8.96)*** 8.07(3.51-18.53)*** 4.92(2.24-10.80)*** 
  DEDTP 10.28(4.29-24.64)*** 13.26(5.16-34.08)*** 4.69(2.16-10.16)*** 14.87(4.94-44.72)*** 23.84(3.15-
180.74)** 
19.13(7.30-
50.14)*** 
17.05(6.46-45.02)*** 25.12(8.07-
78.17)*** 
          Chlorpyrifos metabolite  
TCPY 1.20(0.58-2.48) 0.48(0.15-1.47) 1.03(0.48-2.22) 2.56(1.23-5.34)* 1.93(0.83-4.45) 0.77(0.35-1.68) 1.83(0.89-3.74) 1.40(0.69-2.83) 
II. Pyrethroid metabolites  
Pyrethroids 2.32(1.19-4.52)* 1.07(0.46-2.50) 0.74(0.36-1.50) 2.95(1.48-5.90)** 2.18(0.98-4.88) 2.23(1.14-4.37)* 3.78(1.91-7.50)*** 2.66(1.36-5.19)** 
  cis-DCCA 2.26(1.12-4.58)* 1.44(0.59-3.49) 0.72(0.33-1.57) 2.72(1.32-5.58)** 2.10(0.92-4.80) 1.62(0.78-3.34) 2.96(1.45-6.03)** 2.12(1.06-4.24)* 
  trans-
DCCA 
1.52(0.75-3.11) 0.93(0.36-2.43) 0.65(0.29-1.47) 2.51(1.21-5.20)* 1.21(0.56-2.63) 2.28(1.10-4.73)* 2.12(1.04-4.33)* 1.57(0.78-3.17) 
  DBCA 1.60(0.79-3.24) 1.03(0.40-2.65) 0.76(0.35-1.67) 2.40(1.18-4.91)* 1.74(0.78-3.88) 1.80(0.87-3.70) 2.09(1.03-4.24)* 1.63(0.82-3.25) 
    4F3PBA 2.53(1.23-5.19)* 2.50(1.04-6.00)* 1.48(0.70-3.13) 4.97(2.24-11.04)*** 4.32(1.58-11.82)** 2.94(1.41-6.13)** 3.38(1.63-7.02)** 2.74(1.34-5.61)** 
  3PBA 2.68(1.29-5.57)** 0.95(0.37-2.48) 0.83(0.38-1.81) 2.18(1.05-4.51)* 1.63(0.72-3.69) 2.50(1.17-5.33)* 3.79(1.80-7.97)*** 2.17(1.06-4.42)* 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
66 
 
 
3.6. Association between cytokines and other asthma outcomes  
 
Table 7 summarises the results of adjusted multiple logistic regression models of the 
association between cytokines and other asthma outcomes in this study population. 
Allergic airway inflammation (FeNO>50ppb) was positively associated with all Th2 
(IL-4, IL-5 and IL-13), Th1 (IFN-γ), Th17 (IL-17) cytokines and IL-10 (Table 7). All 
Th2 cytokines were also positively associated with doctor-diagnosed and adult-onset 
asthma.  
 
 
Table 7: Adjusted multiple logistic regression models of the association 
between cytokines and asthma outcomes among rural women in Western Cape 
 
Cytokines Asthma outcomes: Odds Ratio (95% Confidence Interval) 
Doctor-
diagnosed 
asthma 
Adult-onset 
asthma 
Current asthma FeNO: 25ppb–
50ppb 
FeNO > 50ppb 
Th2 cytokines 
IL-4 1.04(0.39-2.75) 1.59(0.56-4.46) 0.64(0.14-3.00) 0.41(0.15-1.15) 1.13(0.31-4.04) 
IL-5 2.17(0.69-6.88) 2.92(0.89-9.57) 0.36(0.02-5.41) 0.64(0.17-2.40) 1.62(0.34-7.64) 
IL-13 1.34(0.51-3.55) 1.15(0.40-3.31) 1.04(0.23-4.79) 0.45(0.15-1.33) 1.34(0.37-4.87) 
Any Th2 1.70(0.63-4.55) 1.87(0.64-5.54) 0.75(0.16-3.45) 0.44(0.17-1.14) 0.70(0.19-2.60) 
Non-Th2 cytokines 
IL-6 1.20(0.46-3.12) 1.60(0.56-4.57) 0.59(0.13-2.71) 0.53(0.21-1.36) 0.62(0.17-2.31) 
IL-8 0.85(0.30-2.36) 1.05(0.33-3.28) 0.58(0.12-2.78) 0.34(0.13-0.89)* 0.50(0.12-2.16) 
IL-10 1.09(0.39-3.03) 1.53(0.52-4.47) 0.45(0.06-3.22) 0.37(0.12-1.17) 1.25(0.33-4.71) 
IL-17 0.96(0.37-2.53) 1.12(0.40-3.14) 0.89(0.20-3.92) 0.53(0.20-1.41) 1.08(0.30-3.82) 
IFN-γ 0.77(0.30-1.99) 0.70(0.25-1.98) 0.33(0.07-1.67) 0.36(0.13-0.98)* 1.33(0.38-4.68) 
Any non-
Th2 
0.85(0.30-2.36) 1.05(0.33-3.28) 0.58(0.12-2.78) 0.34(0.13-0.89)* 0.50(0.12-2.16) 
*p<0.05; Any Th2: any of IL-4, IL-5 or IL-13; Any non-Th2: any of IL-6, IL-8, IL10, IL-17 or IFN-γ;  
Cytokines categorised as detected vs. non-detected 
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4. Discussion 
 
This study demonstrated that OP and PYR metabolite levels in rural women in the 
Western Cape are higher than in the general population. Using these exposure proxy 
markers, the findings of this study suggests that both OP and PYR pesticides are 
associated with asthma, which may be due to Th2 and non-Th2 mechanisms, the 
latter pathway demonstrating consistently stronger relationships.  
 
The DAP levels detected in this study were higher than levels found among general 
population in the US [33] and in the Netherlands [34], and also generally higher than 
concentrations among pesticide applicators in Peru [35]. However, the levels of DAP 
detected in this study were generally lower compared to levels among applicators 
and general farm workers in a previous study in the Western Cape province of South 
Africa [17] as well as pesticide applicators in Japan [36] and Italy [37]. The possible 
reason for the lower levels of DAP found in this current study compared to these 
studies in other settings [17,36,37] could be due to the very low number (only 4) of 
pesticide applicators among the total number of study participants, a large proportion 
who were general farm labourers.  
 
TCPY is a short-term marker of exposure to both chlorpyrifos and chlorpyrifos-methyl 
[1,37]. TCPY levels in this current study were higher than levels found among the 
general population in the Netherlands [34] and in the US [38]. Furthermore, the 
proportion of TCPY detected in this study was higher than in US Latino farm workers 
[39]. However, when TCPY levels found in this study are compared to farm workers 
(pesticide applicators and other workers) in Italy, participants in this study had lower 
median levels than their Italian counterparts [37]. Interestingly, TCPY levels in our 
study, which were measured from spot urine samples, were comparable to the 24 
hour urine TCPY concentrations reported for the general population in Italy [40]. To 
our knowledge, no previous study has measured TCPY levels in farming or non-
farming communities in South Africa. 
 
DBCA is a specific metabolite of deltamethrin while 4F3PBA is a specific metabolite 
of cyfluthrin [18] . Cis- and trans-DCCA are the metabolites of permethrin, 
cypermethrin and cyfluthrin [18]. On the other hand, 3PBA is a non-specific 
metabolite, common to about 20 synthetic pyrethroids including permethrin, 
cypermethrin, cyfluthrin and deltamethrin [18,41]. In our study, DBBA and 4F3PBA 
were the highest PYR metabolites detected in urine samples implying that the study 
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participants were more exposed to deltamethrin and cyfluthrin than the other 
pyrethroids. The levels of PYR metabolites detected in this study were higher than 
levels reported among individuals from the general population in Germany [42], 
Poland [43], Italy [44], US [45] and Japan [46]. Furthermore, the proportion of PYR 
metabolites detected in our study were substantially higher than in US Latino farm 
workers [39]. The levels of 3PBA in our study were higher than levels reported 
among Japanese workers involved with farming activities including spraying 
pesticides [46] but similar to US forestry workers exposed to pesticides [47]. When 
compared to flight attendants exposed to pyrethroids, 3PBA and trans-DCCA levels 
in our study were lower while DCBA and 4F3PBA levels were higher and cis-DCCA 
levels similar to the levels found in flight attendants [41]. 
 
In this study, individuals who lived in the surrounding towns near the farms were also 
exposed to OP and PYR pesticides based on the results of the urinary 
determinations of pesticide metabolites. It is likely that these workers who do not live 
on the farms may be exposed to pesticides either through pesticide drift as a result of 
living in towns close to farming activities or other environmental exposures such as 
contaminated surfaces, food and water or through household use of pesticides [17]. 
This suggests that characterising exposure according to the place of residence or 
work (whether farm or town dwellers) in rural populations living near farms may not 
always be accurate and other means of validating exposure through more objective 
markers such as those used in this study may provide an alternative approach.  
 
In this current study, IL-13 levels were higher among town dwellers compared to farm 
dwellers. Moreover, town dwellers were more likely to be atopic, and more likely to 
be sensitised to storage and spider mites than farm dwellers. Furthermore, the Th2 
cytokines were positively associated with allergic airway inflammation (FeNO > 50 
ppb), with a larger proportion (9%) having such high levels compared to farm 
dwellers. These findings suggest that the allergic asthma phenotype is more 
dominant entity in this group probably associated with indoor and outdoor mite 
allergens [48].   
 
In this study, a greater proportion of non-Th2 cytokines (71%) were detected than 
Th2 cytokines (52%). Furthermore, while OP and PYR metabolites were positively 
associated with both Th2 and non-Th2 cytokines, stronger associations were 
observed between non-Th2 cytokines and pesticide metabolites. This suggests that 
non-Th2 pathways may be playing a dominant role in the airway inflammation 
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observed in individuals exposed to pesticides. This is consistent with recent studies 
that have implicated non-Th2 pathways such as Th1 and Th17 in the pathogenesis of 
asthma especially in severe, persistent asthma [21,48]. Non-Th2 cytokines such as 
IL-8 and IL-17 have also been linked to neutrophilic asthma [49,50], suggesting that 
this may be an important phenotype associated with OP and PYR pesticide 
exposures.  
 
A more detailed analysis of cytokine patterns in the Th2 pathway, also demonstrated 
that both OP and PYR metabolites were positively associated with Th2 cytokines. 
Furthermore, most of the OP metabolites were also positively associated with allergic 
airway inflammation (FeNO > 50 ppb). Additionally, Th2 cytokines were also 
consistently positively associated with allergic airway inflammation (FeNO > 50 ppb). 
Together, these findings suggest an involvement of Th2 mechanisms in the airway 
inflammation observed in individuals exposed to these OP and PYR pesticides. While 
the few case reports of asthma due to these pesticides previously reported in the 
literature [51–54] could not identify the pathophysiological mechanisms that were 
responsible, a recently published study [55] reported the case of a 29 year old 
woman who developed anaphylaxis after exposure to pyrethroids, implying that these 
pesticides may induce an allergic response. An association between pesticide 
exposure and allergic asthma has also been reported in other epidemiological 
studies [9,56]. 
 
The positive association observed between most of the OP metabolites and allergic 
airway inflammation (FeNO > 50 ppb) in our study is consistent with the findings from 
a previous sub-study [3] of this group, which demonstrated an association between 
low levels of ChE and FeNO. However, the association with FeNO in this current 
study was weaker than in the previous study. The latter could be due to the fact that 
the low ChE levels measured in the previous study also indicate carbamate exposure 
in addition to OP exposure. Carbamates which were not measured in the current  
study, have also been associated with asthma in the literature [9,13].  
 
To our knowledge, no previous epidemiological studies have investigated the effect 
of pesticide exposure ascertained through urinary pesticide metabolite 
concentrations on allergic airway inflammation as determined by FeNO. Furthermore, 
the relationship between pesticide metabolites and cytokine pathways has also not 
been previously studied, suggesting the use of novel insights into the mechanisms 
underlying asthma associated with pesticides. However, there are some limitations of 
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using this approach. The lack of strong association between the measured pesticide 
metabolites and some asthma outcomes in our study could have been due to the 
cross-sectional study design. This may have resulted in a healthy worker effect 
whereby individuals who developed adverse health effects from pesticides may have 
left their employment on the farms to work in other alternative jobs. The short half-life 
of these OP and PYR metabolites, markers of short-term exposure, may have also 
contributed to the lack of strong association being observed, especially when these 
were related to long term asthma outcome variables such as doctor-diagnosed and 
adult-onset asthma. This is suggested by the fact that stronger associations were 
found with short-term outcomes such FeNO and current serum cytokine levels. 
Another possible explanation for the lack of strong associations observed between 
pesticide metabolites and some asthma outcomes could be due to the low number of 
pesticide applicators in our study, which may have contributed to a muted exposure 
gradient. Although there was no standardisation of blood sampling for some factors 
such as food intake, use of medications and sleep patterns; it is unlikely that this 
created a systematic error.   
 
In conclusion, this study has shown that OP and PYR metabolite levels in rural 
women in the Western Cape are higher than in general population. Furthermore, it 
provides evidence suggesting that both OP and PYR pesticides are associated with 
asthma. The cytokine patterns suggest that while non-Th2 cytokines play a major 
role, Th2 cytokines are also associated with airway inflammation in individuals 
exposed to pesticides. Apart from these immunological (Th2 and non-Th2) 
mechanisms, pesticides can also act as irritants and interact with their functional 
irritant receptors resulting in asthma [57].  
 
The study findings suggest that greater efforts should be made to protect farm 
workers and the surrounding farming communities from the respiratory health risks 
associated with pesticides. Farm workers, managers and owners should be educated 
about the proper use of pesticides and their adverse respiratory health effects.  
Furthermore, workers at high risk should undergo regular medical surveillance 
including biomonitoring for urinary pesticide metabolites to assess that adequate 
control measures are in place to protect their health.  
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Health effects due to pesticide exposure amongst rural women in the 
Western Cape 
 
                                                             
                                              UNIVERSITY OF CAPE TOWN 
 
 
 
 
Study Number              ______ 
 
Date      ________________ 
 
Area      _______________________________ 
 
Farm Name     _______________________________  
  
Name of Interviewer    _______________________________               
 
 
GENERAL INSTRUCTIONS 
 
Thank you for agreeing to take part in this study. 
 
We will work through the questionnaire as follows: I will ask the questions and give 
you the answer choices and tick or circle the answers you give me in the 
questionnaire. Choose the answer that is the closest to how you feel.  
 
Please note that there are no right or wrong answers to the questions asked. Please feel 
free to answer just what you think. You may stop at any time if you do not want to 
carry on with these questions. Your answers are confidential and will not be shared 
with anyone. Only the research staff will have access to the questionnaire once it has 
been completed.    
 
 
 
Section 1:  DEMOGRAPHIC CHARACTERISTICS 
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We would like to ask you a few questions about yourself. 
 
1.1    How old are you? _________ (years) 
        Date of birth  ____/_____/_____ 
 
1.2   What is the highest level of education you have passed? 
Less than one year completed 1 
Sub A/Class 1/Grade 1 2 
Sub B/Class 2/Grade 2 3 
Standard 1/Grade 3 4 
Standard 2/Grade 4 5 
Standard 3/Grade 5 6 
Standard 4/Grade 6 7 
Standard 5/Grade 7 8 
Standard 6/Grade 8 9 
Standard 7/Grade 9 10 
Standard 8/Grade 10 11 
Standard 9/Grade 11 12 
Standard 10/Grade 12 13 
Further studies – incomplete 14 
Diploma/other post school – complete 15 
Degree 16 
 
 
1.3 Which main language do you speak at home? _________________ 
 
 
Section 2: HOUSEHOLD FACTORS 
 
2.1       Is the house you live in:  
  
Owned by your family  
 
1 
Rented  
 
2 
Owned by the owner of the farm 3 
Other (please specify) 4 
   
           Specify _________________________________ 
2.2 Does your house have: 
  Yes No 
A Electricity   
B A radio   
C A television   
D A landline telephone   
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E A fridge   
F A computer   
G A washing machine   
H A cell phone (anybody) 
 
 
 
 
2.3 How many people usually live and sleep in your household? 
 Number of people 
 
 
Section 3:  ECONOMIC FACTORS 
 
Now we would like to ask a few questions about you and the work that you do. 
 
3.1 What kind of work do you do? (If working, please tell me your occupation. For          
example, Farmer, Street Trader, Primary School Teacher, Domestic Worker) 
 
Not working No 
Working  
 
Yes 
If working,  specify  
 
3.2     Please indicate which of the following are your sources of income. Please    
              answer this question whether or not you are working.  
 
 
 
Yes No 
A Work   
B Spouse/partner   
C Parents   
D Brothers and/or sisters   
E Children   
F Child Support Grant   
G State Old Age Pensions   
H Disability Grant   
I Care Dependency Grant   
J Foster Care Grant   
K Grants-in-Aid   
L Workman’s Compensation Fund   
M Other (Please specify)   
3.3 What is your household income? ____________________ 
3.4 How often do the people in your family go hungry or have no food to eat? 
Never 0 
Seldom 1 
Sometimes 2 
Often 3 
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3.5 During which months of the year do you go hungry? __________________ 
(months of year). 
 
Section 4. RESIDENTIAL HISTORY 
 
Now I’d like to ask you a few questions about the places where you have lived in 
your lifetime: 
 
4.1 Where do you currently live (Town, city, farm)?  ____________ 
 
How long have you lived here? ____________________ (Years/Months) 
 
If on a farm, 
 
4.2 What kind of farm is this? (what is grown here?)  ______________________ 
 
    4.2.1 Is this an export farm? ________ (Yes, No) 
                       If yes, where are crops exported to? _______________________ 
(countries) 
 
    4.2.2 Is this a Tesco farm _________ (Yes, No) 
 
 
4.3 How far from your house is the nearest vineyard/orchard? _______________ 
(meters) 
 
 
4.4 Are pesticides sprayed on the vineyard/orchard during the year?  ____ (Yes/No) 
 
4.5 When last was pesticides applied in the vineyard/orchard? ________ (number of 
days) 
 
                      
IF YES, complete the following: 
 
4.5  How many months a year are pesticides applied on the farm ______  
 
How many days per month are pesticides applied during the spraying months? _____ 
 
Number of days per year ________ 
                                   
 
4.6  Does the pesticides spraying come into the house?  ________ (Yes/No) 
  
4.7  Do you  come into contact with pesticides  
        outside the house while spraying occurs (e.g.  
        hanging your washing?                                       .  _________ (Yes/No) 
 
4.8 Who apply pesticides on this farm _______________(Men, Women, Both) 
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4.9 Does the farmer provide you with protective clothes and equipment (including 
gloves,  
      masks, overalls, etc? _________ 
                If yes, is it free of charge? __________ (Yes, No) 
 
 
 
4.10 Are shower/washing rooms provided for workers coming into contact with 
pesticides? 
 
       ___________ (Yes, No)   
       
4.11 When spraying happens, are workers expected to work in sprayed blocks? 
___(Yes, No) 
 
4.12 How soon after spraying/application of pesticides do you return to the  
        vineyard/orchard?  __________ (number of days) 
 
4.13 What is the method of pesticide application?  __________ (Tractor, backpack or 
other  
         methods) 
 
4.14 What are the sources of drinking water at your house? ____________________     
        (municipal water, storage dam on mountain, borehole/spring, river water, farm  
        dam, rain water tank, etc) 
 
4.15 What are the sources of water for recreational use (bathing, washing of clothes)  
        at your house? ____________________ (municipal water, storage dam on  
        mountain, borehole/spring, river water, farm dam, rain water tank, etc) 
 
4.16 Did you live elsewhere before? _____ (Yes/No) 
 
 
If YES, 
 
Please provide the details about the places where you have lived PREVIOUSLY in 
the following table: 
 
 
Places lived previously 
1 2 3 4 5 6 7 8 9 10 11 
Number of years            
Was pesticides 
sprayed on the farm? 
           
 
 
4.12 Were you born on a farm where pesticides were applied? ___ (Yes/No) 
 
 
      Section 5.  WORK HISTORY 
 
Current job 
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5.1 What is your current occupation? _______________ 
 
5.2 What is your job title? ________________________ 
 
5.3 For how many years have you worked in this job? __________ (years) 
 
5.4 Do you currently work on a farm? ___ (Yes/No) 
 
 
If you work on a farm, 
 
5.5 Are you a permanent or seasonal farm worker? _________________ 
 
5.6 If you do not live on the farm you work at: 
  
      5.6.1 Which crops are produced on the farm 
_______________________________ 
      5.6.2  Is the farm you work on an export farm? ________ (Yes, No) 
                       If yes, where are crops exported to? _______________________ 
(countries) 
 
      5.6.3  Is the farm you work on a Tesco farm? _________ (Yes, No) 
 
 
5.7.1 Do you work in the field? ________ (Yes/No) 
 
5.7.2 Do you apply (spray/mix) pesticides ______        (Yes/No)  
 
5.7.3 If YES which pesticides do you use _______________________________ 
 
_________________________________________________________________ 
 
            5.7.4 When last did you apply pesticides? __________ (number of days)    
 
5.7.5 How many months a year do you apply pesticides? _________ 
 
How many days per month do you apply pesticides in the spraying months? _______ 
 
Total number of days per year _____ 
 
5.7.6 Do you drive a tractor while others spray pesticide? _______(Yes/No) 
            If yes, how many times per year? __________ 
 
5.7.7 Which Personal Protective Equipment do you use? _____________ 
         (Indicate with A = Apron, B = Boots, G = Gloves, M = Mask, O = Overalls, Gls  = Goggles)  
 
5.78  Is PPE provided free of charge? __________ (Yes, No) 
 
Previous jobs 
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Please provide the details about your PREVIOUS work in the following table 
 
 
Previous jobs 
1 2 3 4 5 6 7 8 9 10 11 
Number of years            
Work on a farm  
(Yes, no) 
           
Occupation 
 
           
Job Title 
 
           
If on farm:            
Do you work in the 
field?  (Yes, No) 
           
Do/did you apply 
(spray or mix) 
pesticides (Yes, No) 
           
How many days per 
year do/did you apply 
pesticides? 
           
Were you the tractor 
driver ? (Yes, No) 
           
How many days per 
year were you the 
tractor driver? 
           
Which PPE did you 
use?* 
           
*Indicate with A = Apron, B = Boots, G = Gloves, M = Mask, O = Overalls, Gls  = Goggles 
 
 
Section 6. ALCOHOL USE 
                          
6.1 Do you drink alcohol or did you drink before ___________? (Yes/No) 
If yes, 
6.2 Have you ever felt that you should drink less alcohol?                       ____ 
(Yes/No) 
 
6.3 Have people ever angered you by criticising your drinking habits?   ____ 
(Yes/No) 
 
6.4 Have you ever felt guilty or bad because you drink alcohol?              ____ 
(Yes/No) 
 
6.5 Have you ever had a drink early in the morning to make you  
      feel better or to get over a ‘babalaas’?                                                 ____ 
(Yes/No) 
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 Section 7.  SMOKING AND OTHER DRUG USE 
 
7.1 Have you ever smoked tobacco (cigarettes or pipe) for as long as a year? ____ 
(Yes/No) 
 
(‘Yes’ means at least 20 packs of cigarettes or 30 grams of tobacco in a lifetime or at least one 
cigarette per day for one year) 
 
If Yes,  
 
    7.1.1  How old were you when you started smoking? ____ (years) 
 
    7.1.2 Do you smoke currently? ___ (Yes/No) 
     (‘Yes’ means smoking tobacco in the last month or more) 
 
7.1.3 If no, how old were you when you stopped smoking? _________ 
7.1.4 How much do/did you now smoke on average? 
 
               Number of cigarettes per day ____ 
 
              Pipe tobacco in grams/week _______ 
 
  7.1.5 Do you or did you inhale the smoke? ____ (Yes/No) 
 
7.2  Have you been regularly exposed to tobacco smoke from other people smoking 
cigarettes or pipe in the last 12 mon hs? 
(‘Regularly’ means on most days or nights) 
 
7.3 Do you take drugs or have taken drugs before? ________ (Yes/No) 
 
7.3.1 If YES, please state for how many years __________ (years) 
 
 
Section 8.  HOUSEHOLD PESTICIDE USAGE 
 
 
8.1 Do you or any one in your house use pesticides in the garden 
      or in your home?____ (Yes/ No) 
   
        If yes, what do you use? ____________________________________________ 
 
 
8.2 Do pesticide contaminated clothes get washed at home? ____ (Yes/ No)          
    
8.4 If yes, does it get washed with the rest of the washing? _____ (Yes/ No) 
 
8.5 Do you eat fruit or vegetables from your garden ? _____ (Yes / No) 
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8.6 Do you use empty pesticide containers at home for domestic  
      purposes? ____(Yes/ No) 
      
8.7 If yes, what do you use them for? _____________________________________ 
        
 
Section 9 MEDICAL, REPRODUCTIVE AND RESPIRATORY HISTORY 
 
9.1 Do you suffer from : 
Asthma          _______ (Yes/No) 
Bronchitus     _______ (Yes/No) 
TB                  _______ (Yes/No) 
Eczema          _______ (Yes/No) 
Hayfever        _______ (Yes/No) 
Farmers Lung _______ (Yes/No) 
Other diseases: ______ (Yes/No)   if yes, specify _____________________ 
 
9.2 What was your weight at birth _______________ 
9.3 At what age did you reach puberty? _______ 
9.4 Did you ever experience pesticide poisoning that was confirmed by a doctor?  
            ____(Yes, No) 
 
If yes, how many times__________ 
 
9.5 Do you frequently feel/have : 
            Dizzy         _______ (Yes/No) 
            Nauseas     _______ (Yes/No) 
            Headaches _______ (Yes/No) 
            Skin, nose and/or eye irritation ______ (Yes/No) 
            Skin rashes ______ (Yes, No) 
            Nauseas and want to vomit (Yes, No) 
            Cold or open sores ______ (Yes, No) 
             
Section 10 (Q16)    
      
10.1. Are you abnormally tired?                                                                       ____ (Yes / No) 
                    
10. 2. Do you have palpitations of the heart when you do not exert yourself? ____ (Yes/No)                  
 
10. 3. Do you often have painful tingling in some part of your body?              ____ (Yes/No)                
              
10. 4. Do you often feel irritated without any particular reason?                       ____ (Yes/No)                
  
10. 5. Do you often feel depressed without any particular reason?                    ____ (Yes/No)         
               
10.6. Do you often have problems concentrating?                                             ____ (Yes/No)  
                           
10. 7. Do you have a short memory?                                                                  ____ (Yes/No)  
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10. 8. Do you often perspire without any particular reason?                               ____ (Yes/No)             
   
10. 9. Do you have any problems with buttoning and unbuttoning?                   ____ (Yes/No)                  
   
10.10 Do you generally find it hard to get the meaning from reading  
           newspapers and books?                                                                             ____ (Yes/No)  
                    
10. 11.Have your relatives told you that you have a short memory?                   ____ (Yes/No)                
  
 
10. 12. Do you sometimes feel a heavy feeling on your chest?                           ____ (Yes/No)                         
   
10. 13. Do you often have to make notes about what you must remember?       ____ (Yes/No)      
                                                                     
10. 14. Do you often have to go back and check things you have done such 
            as locking the door?                                                                                 ____ 
(Yes/No)                    
10. 15. Do you have a headache at least once a week?                                        ____ (Yes/No)   
                
10. 16. How many times do you have sex per week?                                          ____ (Yes/No)                      
 
10. 16a. Do you think that this is less than most persons of your age?                ____ (Yes, No)        
        
Section 11. Time to pregnancy 
 
11. 1. Have you ever been pregnant? ________ (Yes/No) 
 
11. 2. If yes, how many times? ______ 
 
11. 3. List how many pregnancies ended in  
 
    Live birth             ____  
    Stillbirth               ____  
    Miscarriage          ____  
    Ectopic/Tubal pregnancy ____  
    Other                   ____ 
  
11.4 FOR LIVE BIRTHS AND STILLBIRTHS ONLY (omit twins) Fill in the 
following     
        Table: 
 
 
Pregnancy 
1 2 3 4 5 6 7 8 9 10 11 
Weight of baby (kg)            
During the month this 
pregnancy was 
conceived, were you 
or your husband 
using any form of 
birth control? (Yes, 
No) 
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Method of  birth 
control* 
 
           
Were you using birth 
control all the time, 
nearly all the time, or 
only sometimes? 
 
           
If NO BIRTH 
CONTROL  or 
ONLY 
SOMETIMES: 
How many months 
did it take you to get 
pregnant? 
           
*oral (the pill), intrauterine device (coil, loop), condoms, diaphragm (cap), rhythm or withdrawal, other 
 
 
Section 12. ALLERGIC HEALTH PROBLEMS 
 
12.1 Have you had wheezing or whistling in your chest at any time  
        in the last 12 months? ______ (Yes/No) 
 
If yes, go on to Question 12.2 
If no, go on to Question 12.4 
 
12.2 Have you been short of breath when the wheezing noise was present? _____ (Yes/No) 
 
12.3 Have you had this wheezing or whistling when you did not have a cold or flu? ___ (Yes/No) 
 
12.4 Have you been woken up with a feeling of tightness in your chest at any 
        time in the last 12 months? _____ (Yes/No) 
 
12.5 Have you had an attack of shortness of breath that came on during the daytime when you were 
at   
        rest at any time in the last 12 months? ____ (Yes/No) 
 
12.6 Have you been woken by an attack of coughing at any time in the last 12     
        months? _____ (Yes/No) 
 
 
12.7 Have you ever had asthma? ____ (Yes/No) 
 
If Yes, go on to Question 12. 
If No, skip to next Question 
 
12.8 If yes, was this confirmed by a doctor? 
 
12.9 How old were you when you were told you have asthma? _______ (years) 
 
12.10 Have you had an attack of asthma in the last 12 months? _____ (Yes/No) 
 
12.11 Are you using any medicines, including inhalers/pumps, nebulizers,  
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          syrups or tablets, for asthma or breathing problems? ____ (Yes/No) 
 
12.12 When you are near animals, feather or in a dusty part of the house, do you ever get a feeling 
of   
          tightness in your chest? ____ (Yes/No) 
 
12.13 Do you get a tight chest or wheeze when you work in the: 
          12.13.1 Vineyard/Orchard ____ (Yes/No) 
          12.13.2 Packing room ____ (Yes/No) 
          12.13.3 Other ____ (Yes/No) If yes, specify _____________________________ 
 
12.14 Have you had any nasal allergies including hay fever or itchy and watery  
          eyes/nose in the last 12 months? ____ (Yes/No) 
 
12.15 Do you get itchy/watery eyes or nose when you work in the: 
          12.14.1 Vineyard/Orchard ____ (Yes/No) 
          12.14.2 Packing room ____ (Yes/No) 
          12.14.3 Other ____ (Yes/No) If yes, specify _____________________________ 
 
12.16 Have you had any skin problems in the last 12 months? ____ (Yes/No) 
 
 
12.17 Do you get red, itchy pimples when you work in the:  
          12.17.1 Vineyard/Orchard ____ (Yes/No) 
          12.17.2 Packing room ____ (Yes/No) 
          12.17.3 Other ____ (Yes/No) If yes, specify _____________________________ 
 
Thank you for taking part in this study 
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Appendix A2 
Afrikaans Questionnaire 
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Gesondheids gevolge weens blootstelling aan gifstowwe op landlike 
vrouens in die Weskaap 
 
                                                             
                                              UNIVERSITEIT VAN KAAPSTAD 
 
 
 
 
Vraelysnommer            ______ 
 
Datum     ________________ 
 
Area      _______________________________ 
 
Naam van plaas    _______________________________  
  
Naam van 
Onderhoudvoerder     _______________________________               
 
 
ALGEMENE INSTRUKSIES 
 
Dankie dat jy ingestem het om aan hierdie studie deel te neem.  
 
Ons gaan soos volg deur die vraelys werk: Ek sal die vrae vra en aan jou die 
moontlike antwoordkeuses gee en ek sal jou antwoorde merk en omsirkel in die 
vraelys. Kies die antwoord wat die naaste is aan hoe jy voel.  
 
Let asseblief op dat daar geen regte of verkeerde antwoorde op die vrae is nie. 
Antwoord asseblief soos jy voel. Jy kan enige tyd ophou as jy nie wil voortgaan met 
die vrae nie. Jou antwoorde is vertroulik en sal aan niemand anders bekend gemaak 
word nie. Slegs die navorsingspersoneel sal toegang tot die vraelys hê nadat dit 
voltooi is.  
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Afdeling 1:  DEMOGRAFIESE BESONDERHEDE 
 
Ons wil jou graag ’n paar vrae oor jouself vra.  
1.1    Hoe oud is u?  _________(jaar) 
       Geboortedatum  ____/_____/_____ 
 
1.2   Wat is die hoogste vlak van onderrig wat jy geslaag het? 
Minder as een jaar voltooi 1 
Sub A/Klas 1/Graad 1 2 
Sub B/Klas 2/Graad 2 3 
Standerd 1/Graad 3 4 
Standerd 2/Graad 4 5 
Standerd 3/Graad 5 6 
Standerd 4/Graad 6 7 
Standerd 5/Graad 7 8 
Standerd 6/Graad 8 9 
Standerd 7/Graad 9 10 
Standerd 8/Graad 10 11 
Standerd 9/Graad 11 12 
Standerd 10/Graad 12 13 
Verdere onderrig – onvoltooid 14 
Diploma/ander naskools – voltooid 15 
Graad 16 
 
1.3 Wat is die taal wat die meeste tuis gepraat word? ______________________ 
 
 
Afdeling 2: INLIGTING OOR HUISHOUDING 
 
2.2  Is die huis waarin jy woon:  
  
Die eiendom van jou gesin 
 
1 
Gehuur  
 
2 
Die eiendom van die plaaseienaar 3 
Ander (spesifiseer asb.) 4 
  
           Spesifiseer asseblief _________________________________ 
2.2 Is die volgende in jou huis: 
  Ja Nee 
A Elektrisiteit   
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B ’n Radio   
C ’n Televisie   
D ’n Landlyntelefoon   
E ’n Yskas   
F ’n Rekenaar   
G ’n Wasmasjien   
H ’n Selfoon (enige iemand) 
 
 
 
 
 
2.3 Hoeveel mense woon en slaap gewoonlik in jou huishouding? 
 Aantal mense 
 
 
Afdeling 3:  EKONOMIESE FAKTORE 
 
Nou wil ons graag ’n paar vrae oor jou en die werk wat jy doen, vra. 
  
3.2 Watter soort werk doen jy? (Indien jy werk, wat is jou beroep? Byvoorbeeld 
boer, straathandelaar, laerskoolonderwyser, huishulp) 
Werk nie Nee 
Werk  
 
Ja 
Indien u werk,  spesifiseer  
 
 
3.2     Dui asseblief aan watter van die volgende is jou bronne van inkomste. 
Antwoord asseblief hierdie vraag – of jy werk of nie.   
 
 
 
Ja Nee 
A Werk   
B Eggenoot/lewensmaat   
C Ouers   
D Broers en/of susters   
E Kinders   
F Kinderonderhoudstoelae   
G Staatsouderdomspensioen    
H Ongeskiktheidstoelae   
I Sorgafhanklikheidstoelae   
J Pleegsorgtoelae   
K Hulptoelae   
L Vergoeding vir beroepsbeserings   
M Ander    
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Indien ander, spesifiseer asseblief ________________________________________ 
 
3.3 Wat is u totaal huishoudelike inkomste? ____________________ 
 
3.4 Hoe gereeld ly die mense hier honger of het nie kos om te eet nie?(please tick) 
Nooit  
Selde  
Soms  
Dikwels  
 
 
3.5 Gedurend watter maande van die jaar, ly u honger? 
____________________________ 
 
________________________________________________________ (maande van 
die jaar) 
 
 
Afdeling 4. LEWENSGESKIEDENIS 
 
Nou wil ek jou graag ’n paar vrae vra oor die plekke waar u al in jou leeftyd 
gewoon het:  
 
4.1 Waar woon jy nou? (Dorp, stad, plaas)?  ____________ 
 
Hoe lank woon jy al hier? _____________________(jare/maande) 
 
Indien op ‘n plaas woon nie, skip na vraag 4.15 
 
4.2 Watter soort plaas is hierdie (waarmee word hier geboer)? 
________________________ 
       
       4.2.1 Is hierdie plaas ‘n uitvoerplaas? ____ (Ja/Nee) 
               Indien ja, waarnatoe uitvoer hierdie plaas hul gewasse? 
______________________ 
                
              _______________________________________________ (lande) 
 
       4.2.2 Is hierdie ‚n Tesco plaas? ____ (Ja/Nee) 
 
 
4.3 Hoe ver is jou huis van die naaste wingerd/lande? __________________(meters) 
 
4.4 Word gifstowwe gedurende die jaar op die wingerd/lande gespuit? ____ (Ja/Neee)  
 
4.5 Wanneer laas was daar gifstowwe aangewend op die  
       wingerd/boord. ______________  (aantal dae) 
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Indien Ja, Voltooi die volgende: 
 
4.6 Hoeveel maande ’n jaar word gifstowwe op die plaas aangewend? ___________ 
 
       Hoeveel dae in die maand word gifstowwe aangewend gedurend die 
       bespuiting maande? ________________ 
        
       Aantal dae in ‘n jaar  ________ 
 
4.7  Kom die gifstowwe in die huis in? ____ (Ja, Nee) 
 
4.8 Kom u in kontak met gifstowwe buite die huis terwyl daar gespuit word?  
       (b.v. wanneer u wasgoed buitekant gaan op hang)? ____(Ja, Nee) 
 
4.9 Wie wend gifstowwe aan op die plaas? _________________ (Mans, vrouens, 
albei) 
   
4.10 Voorsien die plaas eienaar/bestuurder u vir klere van beskerming en  
        Toerusting?(b.v. handskoene, oorpakke en maskers ens.) ____ (Ja/Nee) 
            Indien ja, is dit gratis? ____ (Ja/Nee) 
 
4.11 Het die plaas ’n stort vir plaaswerkers wie in aanraking kom  
        met gifstowwe ____ (Ja/Nee) 
 
4.12 Wanneer bespuiting plaasvind, word dit verwag van die werkers om in hierdie 
blokke te    
        werk wat kortliks gespuit was? ____ (Ja/Nee) 
 
4.13 Nadat hulle die gifstowwe aangewend het, hoeveel dae daarna gaan u terug   
        wingerd/boorde toe? ______________ (aantal dae) 
 
4.14 Dui aan hoe u die gifstowwe aanwend:  
 
        Trekker met balkspuit      _____ (Ja/Nee) 
        Trekker sonder balkspuit _____ (Ja/nee) 
        Rugsak                             _____ (Ja/Nee) 
        Quad bike                         _____ (Ja/Nee) 
        Ander                               _____ (Ja/Nee) Indien ja, spesifiseer 
___________________ 
 
4.15 Waar kom die drinkwater in jou huis vandaan? ____________________ 
       (Munisipale water, opgaardam op berg, boorgat/fontein, rivierwater, plaasdam,   
       reënwatertenk, ens.) 
 
4.16 Waar kom die water vir gebruiksdoeleindes in jou huis vandaan (b.v. bad of 
klere   
        was)?____________________________ (munisipale water, opgaardam op berg,    
        boorgat/fontein, rivierwater, plaasdam, reënwatertenk, ens.) 
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4.17 Het u in die verlede erens anders gewoon? _____ (Ja/Nee) 
 
Indien Ja, 
 
 
Gee asseblief besonderhede van die plekke waar u IN DIE VERLEDE gewoon het in 
die volgende tafel 
 
 
Plekke in die verlede gewoon 
1 2 3 4 5 6 7 8 9 10 11 
Waar het u gewoon? 
(plaas, dorp, stad) 
 
         
 
Antal jare            
Was gifstowwe 
aangewend op hierdie 
plaas? (Ja/Nee) 
           
 
 
4.18 Was u gebore op ’n plaas waar hulle gifstowwe aangwend het? _____ (Ja/Nee) 
 
 
 
Afdeling 5.  WERKSGESKIEDINIS 
 
Huidige werk 
 
5.1 Wat is u huidige beroep? 
______________________________________________ 
 
5.2 Wat is u werkstitel? ________________________ 
 
5.3 Hoeveel jare doen u die werk? __________ (jare) 
 
5.4 Is u ’n lid van ’n vakbond? ____ (Ja/Nee) 
 
5.5 Werk u huidiglik op ’n plaas? ____ (Ja/Nee) 
 
Indien u op’n plaas werk, gaan voort van vraag 5.6 af 
Indien u nie op ’n plaas werk nie, skip na vraag 5.12 
 
5.6  Is u ‘n permanent of seisoen plaaswerker? ______________________________ 
 
5.7 Indien u nie op die plaas woon waar u werk: 
 
5.7.1 Met watter soort gewasse boer hierdie plaas ____________________________ 
5.7.2  Is hierdie plaas ‘n uitvoerplaas? ____ (Ja/Nee) 
                      Indien ja, waarnatoe uitvoer hierdie plaas hul gewasse? 
___________________ 
                
                      _______________________________________________ (lande) 
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5.7.3 Die plaas waar u werk‚ is dit ’n Tesco plaas? ____ (Ja/Nee) 
 
5.8 Werk u in die wingerd/boord? ___ (Ja/Nee) 
 
5.9 Wend u gifstowwe aan? (mend/spuit) ___ (Ja/Nee) 
        
       5.9.1 Indien Ja, watter gifstowwe gebruik u? 
_______________________________ 
 
_______________________________________________ (name van die gifstowwe) 
 
5.9.2 Wanneer laas het u gifstowwe aangewend? _________ (aantal dae) 
        5.9.3    Hoeveel maande ’n jaar wend u gifstowwe aan? _______(aantal maande) 
 
                        Hoeveel dae in die maand word gifstowwe aangewend gedurend die 
                        bespuiting maande? ________________ 
                        
                        Aantal dae in ‘n jaar  ________ 
 
 
5.10 Ry u ’n trekker terwyl anders, van agter die trekker, spuit? ____ (Ja/Nee) 
Indien ja, hoeveel keer in ’n jaar? ______________________ 
 
5.11 Watter klere van beskerming dra u? _____________________ (Dui aan met V = 
Voorskoot, S =   
           Steuwels, H = Handskoene, M = Masker, GM = Gasmasker, O = Oorpak, SB = Skermbril) 
 
5.12  U klere van beskerming en toerusting, is dit gratis? ___ (Ja/Nee) 
 
 
Vorige werk 
 
Gee asseblief die besonderhede oor jou VORIGE werk met gifstowwe in die 
volgende tabel  
 
 
Vorige werk 
1 2 3 4 5 6 7 8 9 10 11 
Aantal jare            
Op ‘n plaas gewerk  
(Yes, Nee) 
           
Beroep 
 
           
Werkstitel 
 
           
Indien op ‘n plaas:            
het u in die wingerd 
/boord gewerk (Ja/Nee) 
           
Het u (spuit of meng) 
gifstowwe aangewend? 
(Ja/Nee) 
           
Hoeveel dae ‘n jaar het u 
gifstowwe aangewend? 
           
Het u trekker gery?            
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(Ja/Nee) 
Hoeveel dae ‘n jaar het u 
trekker gery? 
           
Watter klere van 
berskerming het u gedra* 
           
*Dui aan met V = Voorskoot, S = Steuwels, H = Handskoene, M = Masker, GM = Gasmasker, O = Oorpak, SB = Skermbril 
 
 
 
Afdeling 6. ALKOHOLGEBRUIK 
                          
6.1 Drink jy alkohol of het u al voorheen alkohol gedrink?                   ____(Ja/Nee) 
Indien Ja, 
6.2 Het jy al gevoel dat jy minder alkohol moet gebruik?                      ____(Ja/Nee) 
 
6.3 Het jy al kwaad geword as mense jou drinkgewoontes kritiseer?     ____(Ja/Nee) 
 
6.4 Het jy al ooit sleg of skuldig gevoel oor jy alkohol gebruik?            ____(Ja/Nee) 
 
6.5 Het jy al ooit vroeg in die oggend gedrink om beter te voel of  
      om jou babelas beter te maak?                                                           ____ (Ja/Nee) 
                                                
 
 
 
 
 
 
Afdeling 7.  ROOK EN ANDER DWELM MIDDEL GEBRUIK 
  
7.1 Het u al ooit al oor ‘n jaar tabak, sigarette of pyp gerook ? ____ (Ja/Nee) 
(‘Ja’ beteken ten minste 20 pakke sigarette of 30 gramme van tabak in ‘n leeftyd of ten minste 
een sigaret ‘n dag vir een jaar) 
 
Indien Ja, 
 
7.1.1 Hoe oud was u toe u begin rook? ____ (jaar oud) 
 
7.1.2 Rook u op die huidige oomblik? ___ (Ja/Nee) 
         (‘Ja’ beteken rook in die afgelope maand of meer) 
 
7.1.3 Indien nee, hoe oud was u toe u ophou? _______ (jaar oud) 
7.1.4 Hoeveel rook u of het u ongeveer gerook? 
 
         Aantal sigarette ‘n dag ____ 
         Pyp tabak in gramme/week ______ 
 
7.1.5 Haal u of het u die rook ingehaal? ____ (Ja/Nee) 
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7.2 In die afgelope 12 maande, was u gereeld bloodgestel aan tabak rook van ander 
mense   
      wie sigarette en pyp rook? ____ (Ja/Nee)  
      (’Gereeld’ beteken op meeste dae en aande) 
 
7.3 Neem u dwelmmiddels of het enige dwelmmiddels voorheen gebruik? ____ 
(Ja/Nee)  
   
      7.3.1 Indien Ja, dui asseblief aan vir hoeveel jare _____ (jare) 
 
 
 
Afdeling 8. GEBRUIK VAN HUISHOUDELIKE GIFSTOWWE 
 
8.1 Gebruik jy enige gifstowwe in jou tuin of in jou huis? ____ (Ja / Nee) 
      (bv. Target of Doom ) 
 
      Indien JA – watter gifstowwe gebruik u? 
__________________________________ 
 
_____________________________________________________________________
_ 
 
8.2  Werk enige ander persoon in die huis met gifstowwe? ____ (Ja/Nee) 
 
8.3 Word klere wat met gifstowwe besmet is, by die huis gewas? ____ (Ja/Nee)            
    
8.4 Indien JA, word dit saam met ander wasgoed gewas? _____ (Ja/ Nee) 
 
8.5 Eet jy vrugte of groente uit jou tuin? _____ (Ja/ Nee) 
 
8.6 Gebruik jy leë plaagdoderhouers tuis vir huishoudelike doeleindes? ____ (Ja/Nee) 
     
8.7 Indien JA, waarvoor gebruik jy dit?  ____________________________________ 
 
 
Afdeling 9. MEDIESE, VOORPLANTING EN ASEMHALING GESKIEDINIS 
 
9.6 Lei u aan: 
Asma             _______ (Ja/Nee) 
Brongitis        _______ (Ja/Nee) 
TB                  _______ (Ja/Nee) 
Ekseem          _______ (Ja/Nee) 
Hooikoors      _______ (Ja/Nee) 
Boer se longe _______ (Ja/Nee) 
Ander siekte:  _______ (Ja/Nee)   indien ja, spesifiseer _____________________ 
 
_________________________________________________________________ 
 
9.7 Wat was u geboorte gewig? _______________ 
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9.8 Op watter ouderdom het u puberteit bereik? _______ 
9.9 Was u al ooit vergif deur gifstowwe wat bevestig was deur ‘n dokter? ____(Ja, 
Nee) 
 
Indien ja, hoeveel keer__________ 
 
9.10 Het u of voel u dikwels : 
            Duiselig         ____ (Ja/Nee) 
            Mislik(naar)   ____(Ja/Nee) 
            Hoofpyn         ____ (Ja/Nee) 
            Prikkeling in u vel, neus of/en oog ______ (Ja/Nee) 
            Vel uitslag      ______ (Ja/Nee) 
            Mislik (naar) en u wil opgooi ____ (Ja/Nee) 
            Verkoue of wonde wat oop is ______ (Ja/Nee) 
 
             
 
Adeling 10 (Q16)    
      
10.1 Voel u buitengewoon moeg ?        (JA/NEE) 
                   
10.2 Het u hartkloppens al het  u nie geoefen  nie  ?                                        (JA/NEE) 
 
10.3 Het u dikwels pynvolle prikkel sensasies in ‘n  
        gedeelte van jou liggaam ?                                                                (JA/NEE)  
                            
10.4 Voel u dikwels geirriteerd sonder enige rede ?                                        (JA/NEE) 
               
10.5 Voel u dikwels teneergedruk sonder enige rede  ?                             (JA/NEE) 
               
10.6 Het u dikwels probleme met konsentrasie ?                   (JA/NEE) 
                            
10.7 Is u kort van gedagte ?                     (JA/NEE)         
                   
10.8 Sweet u dikwels sonder enige rede ?                                                  (JA/NEE)                
   
10.9 Het u enige probleme om u knope vas en los te maak ?                     (JA/NEE)                            
   
10.10 Vind u dit oor die algemeen moeilik om koerante en boeke te verstaan ?         (JA/NEE)                            
     
10.11 Het u familie al vir u gese dat u kort van gedagte is ?                      (JA/NEE)                
  
 
10.12 Voel u soms ‘n swaar drukking op u bors ?                  (JA/NEE)  
  
10.13 Moet u dikwels notas maak oor dinge wat u moet onthou ?         (JA/NEE) 
                                                                     
10.14 Moet u dikwels teruggaan om seker te maak dat u sekere dinge 
          gedoen het  bv. Of die deur gesluit is  ?                                                             (JA/NEE) 
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10.15 Het u ‘n hoofpyn ten minste een keer  per  week ?                                           (JA/NEE)              
 
10.16a. Dink u dat dit minder is as ander persone van u ouderdom ?                        
(JA/NEE)                                
                                                 
Afdeling 11. TYD VAN SWANGERSKAP 
 
11. 1. Was u al ooit swanger? ________ (Ja/Nee) 
 
11. 2. Indien ja, hoeveel keer? ______ 
 
11. 3. Lys hoeveel keer toe u swanger was, het u swangerskap op ge-eindig in:   
 
    Lewendige geboortes  ____  
    Dood geboortes           ____  
    Miskraam                    ____  
    Ectopic/Swangerskap in die eierstok ____  
    Ander  ____ 
  
11.4 VIR LEWENDIGE GEBOORTES EN DOOD GEBORTES ALLENLIK(nie 
tweelings    
        nie) Voltooi die volgende tafel: (gee ’n antwoord vir elke baba) 
 
 
Swangerskap 
1 2 3 4 5 6 7 8 9 10 11 
Gewig van baba (kg)            
Gedurend die maand 
van u swangerskap, 
Het u of u man enige 
vorm van 
geboortebeperkings 
gebruik? (Ja/Nee) 
           
Metode van 
geboortebeperking* 
           
Het u 
geboortebeperkings 
al die tyd, amper al 
die tyd of net 
somtyds gebruik? 
           
Indien NIKS 
GEBOORTEBEPER
KING OF NET 
SOMTYDS: Hoe 
lank het ‘n probeer 
om swanger te word 
           
*mondeling(die pil), gekronkel of lissie, Kondome, diafragma (kap), ritme of ontrekking, ander 
 
11.5 Is gesonheidsdienste toeganklik vir u om die volgende by te woon: 
         
Swangerskap ____ (Ja/Nee) 
              Indien ja, watter dienste (hospitaal, kliniek) ___________________ 
 
Geboorte aan u kinders ____ (Ja/Nee) 
              Indien ja, watter dienste (hospitaal, kliniek) ___________________ 
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Ginekologiesesorg ____ (Ja/Nee) 
 Indien ja, watter dienste (hospitaal, kliniek) ___________________ 
 
Seksuele oorsending siekte ____ (Ja/Nee) 
 Indien ja, watter dienste (hospitaal, kliniek) ___________________ 
 
Ander voorplantingsdienste ____ (Ja/Nee) 
 Indien ja, spesifiseer watter probleeme en watter dienste (hospitaal, kliniek) 
 
_____________________________________________________________________ 
 
         
 
Adeling 12. ALLERGIESE GESONDHEIDSPROBLEEME 
 
12.1 In die afgelope 12 maande, het u ‘n asemfluit of ‘n fluit van keel op u 
        bors al ooit gehad al? ______ (Ja/Nee) 
 
Indien ja, gaan voort met 12.2 
Indien nee, gaan voort met 12.4 
 
 
12.2 Was u kort van asem toe die geluid van die asemfluit teenwoordig was? ____ (Ja/Nee) 
 
12.3 Het u die asemfluit/asemhyg gehad terwyl u nie griep of verkoue gehad het nie ____ (Ja/Nee) 
 
12.4 Het u al ooit wakker kom word deur ‘n gevoel van u bors wat toe trek ? _____ (Ja/Nee) 
 
12.5 In die afgelope 12 maande, het u al ooit ‘n aanval gehad deur kort van asem 
        wees gedurend die dag terwyl u rustig gewees het? ____ (Ja/Nee) 
 
12.6 In die afgelope 12 maande, het u al ooit wakker kom word deur ‘n aanval 
        van hoes ? _____ (Yes/No) 
 
 
 
12.7 Het u al ooit aan asma gelei? ____ (Ja/Nee) 
 
Indien ja, gaan voort met 12.7.1 
Indien nee, skip na vraag 12.8 
 
 
        12.7.1 Indien ja, was dit bevestig deur ‘n dokter? 
         
        12.7.2 How oud was u toe u ingelig was dat u aan asma lei? ______ (jare oud) 
 
         12.7.3 In die afgelope 12 maande, het u ‘n aanval van asma gehad? ____ (Ja/Nee) 
 
         12.7.4 Gebruik u enige medisyne, ingesluit met pompe/opsnuifers, nebulizers,  
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                    stroop of pille vir asma of asemhalingsprobleeme? ____ (Ja/Nee) 
 
12.8 Wanneer u naby diere of in stowwerige gedeeltes is van die huis, kry u ooit 
         ’n gevoel van toetrek in u bors? _____ (Ja/Nee) 
 
 
12.9 As u op ‘n plaas werk, trek u bors toe of ‘n asemfluit wanneer u in die: 
        12.9.1 Wingerd/boord werk ____ (Ja/Nee) 
        12.9.2 Pakstoor werk ____ (Ja/Nee) 
        12.9.3 Ander ____ (Ja/Nee) Indien ja, spesifiseer asseblief ______________________ 
 
12.10 In die afgelope 12 maande, het u al ooit nasaal allergies probleeme saam met  
          hooikoors of kraperige en waterige oe en neus gehad? ____ (Ja/Nee) 
 
12.11 As u op ‘n plaas werk, kry u kraperige/waterige oe of neus wanneer u in die: 
        12.11.1 Wingerd/boord werk ____ (Ja/Nee) 
        12.11.2 Pakstoor werk ____ (Ja/Nee) 
        12.11.3 Ander ____ (Ja/Nee) Indien ja, spesifiseer asseblief ______________________ 
 
 
12.12 In die afgelope 12 maande, het u enige vel probleeme gehad? _____ (Yes/No) 
 
12.13 As u op ‘n plaas werk, kry u rooi kraperige puisies wanneer u in die: 
        12.13.1 Wingerd/boord werk ____ (Ja/Nee) 
        12.13.2 Pakstoor werk ____ (Ja/Nee) 
        12.13.3 Ander ____ (Ja/Nee) Indien ja, spesifiseer asseblief ______________________ 
 
12.4 In die afgelope 12 maande, apart van u werk, was u blootgestel aan enige 
        gifstowwe? ____ (Ja/Nee) 
 
 
DANKIE DAT U AAN HIERDIE STUDIE DEELGENEEM HET 
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Appendix B 
Exhaled Nitric Oxide Pre-test Data Collection Sheet 
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      UCT OCCUPATIONAL ALLERGY AND ASTHMA STUDY AMONG 
           VINEYARD WORKERS IN THE WESTERN CAPE PROVINCE 
    
OF SOUTH AFRICA - 2009 
 
       EXHALED NITRIC OXIDE PRE-TEST DATA COLLECTION SHEET 
Survey Number ________________________ 
A. IDENTIFICATION DATA 
  
1.Surname ____________________________________ 
  
2. First name/s ____________________________________ 
  
3. Work number ____________________________________  
  
4. Date of birth: Day_____Month______Year____ 
   
  
5. Gender: Male                   (1) 
  
Female               (2) 
  
  
8. Interviewer's initials   ______________________ 
  
  
9. Date of interview:   
 Day____Month_________Year______   
 
  
10. Farm: _________________________________________________ 
  
  
B.HEALTH PROBLEMS   
Recent chest infections    
1. Have you had the flu or sinusitis in the past 3 weeks?    
Yes                  (1)   
No                   (2)   
  
2. Are you being treated for Tuberculosis (TB)?   
Yes                  
(1)   
No                   
(2)   
  
2.1 If yes, for how long?  ________months         ________weeks 
  
If YES, to next question, indicate to person that the tests will not be  
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done today. Schedule another appointment in three months time 
since the start of TB medication.        
  
Nose and eye symptoms   
4. Have you ever had any nose or eye problems due to allergies  
and/or hay fever?   
Yes                  (1)   
No                   (2)   
  
  
C. SMOKING HISTORY 
  
1. Do you smoke? 
  
Yes                  (1) 
  
No                   (2) 
  
  
  
1.1 If yes, have you smoked (cigarettes/tobacco) in the last hour?  
Yes                  (1) 
  
No                   (2) 
  
  
D. ALCOHOL CONSUMPTION 
  
1. Do you drink alcohol? 
  
Yes                  (1) 
  
No                   (2) 
  
  
1.1 If yes, when have you last consumed alcohol?  
  
1-2 hours ago (1) 
  
1 day ago (2) 
  
1 week ago (3) 
  
  
1.2 How much alcohol did you consume? 
  
_________________________________________________ 
  
  
E. MEDICATION USAGE (show booklet) 
  
1. Are you taking any medicine/s from a doctor or clinic at the  
moment for asthma, and or hayfever? 
  
Yes                  (1) 
  
No                   (2) 
  
  
1.1 If yes, what are you taking and when last did you take them? 
Names                    No. of hours since last dose 
_______________________________ ____________ 
  
______________________ ________________ ____________   
______________________ ________________ _____________   
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F. PHYSICAL ACTIVITY 
  
1. Do you exercise? 
  
Yes                  (1) 
  
No                   (2) 
  
  
2. When was the last time you exercised?  
  
1-2 hours ago (1) 
  
1 day ago (2) 
  
1 week ago (3) 
  
  
  
G. RECENT FOOD INTAKE 
  
1. Did you have anything to eat or drink in the last hour? 
  
Yes                  (1) 
  
No                   (2) 
  
  
If YES to above question, reschedule test for at least 1 hour later  
the same day or another date.        
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Appendix C 
Exhaled Nitric Oxide Data Collection Sheet 
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      UCT OCCUPATIONAL ALLERGY AND ASTHMA STUDY AMONG 
          
 WOMEN ON FARMS PROJECT IN THE WESTERN CAPE PROVINCE
OF SOUTH AFRICA - 20069
       EXHALED NITRIC OXIDE DATA COLLECTION SHEET
Date: _____________________________
Time __________________
Card 1
Ambient NO concentration (ppb) _________________ 1-3
Ambient temperature (degrees celcius) __________________ 4-5
Survey Number ________________________ 6-8
1. Subject's blood pressure systolic ___________ 9-11
diastolic ___________ 12-14
2. Subject's age (in years) ___________________ 15-16
3.1 Subject's height (in centimetres) ___________________ 17-19
3.2 Subject's weight (in kilograms) ___________________ 20-22
4. Gender: Male                   (1) 23
Female               (2)
5. Effort number (start) ____________ 24-26
6.1 FENo measurement (ppb) 1st effort ____________ 27-29
6.2 FENo measurement (ppb) 2nd effort ____________ 30-32
6.3 FENo measurement (ppb) 3rd effort _____________ 33-35
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Appendix D 
Letter of Approval from Human Research Ethics Committee 
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Appendix E 
Human Research Ethics Committee Annual Progress Report 
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Appendix F1 
English Consent Form 
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Consent to participate in a survey investigating health effects due to pesticide 
exposures on women from the rural Western Cape 
 
1. Title of research project 
 
Health effects due to pesticide exposure amongst rural women residents in the 
Western Cape 
 
2.  Names of the researchers 
     Mohamed  Aqiel Dalvie (BSc, Honours, MSc, PhD) 
     Algernon Africa (BTech) 
     Vicky Major (MSc) 
     Lungiswa Giwane 
     Jean May 
       
3.  Purpose of research 
 
    This study is being conducted by The University of Cape Town to investigate  
    the health effects of pesticides on women in the Western Cape.  We would like to  
    conduct measurements on you. The study will be of benefit to women living in  
farming areas and   
    who are exposed to pesticides in the environment. 
 
4. Description of the research project 
 
     Your son will be required to produce a urine and 2 blood samples and undergo a 
respiratory test and  
      you will complete a questionnaire.  
 
a) Questionnaire:  A member of our study team will interview you in privacy to 
complete the questionnaire. You will be asked questions about general 
personal information, your general medical health, and lifetime environmental 
exposure to pesticid s.  
     b)   Urine sample:  Your will produce a urine sample (in privacy) in  
            a plastic container and  give it to the nurse.  The sample will be analysed for 
pesticides. 
 
     c)    Blood sample:  A nurse will draw 14 ml blood from a vein on your arm.  The 
blood will  
            be analysed for to test your allergy status and for pesticide residues.   
 
d) Respiratory test: A nurse will perform a respiratory test.   
  
5. Risks and discomforts of the research 
 
a) From the blood tests. A single needle stick will be felt when the blood is 
taken. Sometimes a small bruise may occur from the needle stick, but this 
is minor and will heal quickly.  The total amount of blood taken is quite 
small and the body will quickly replace it. Blood samples will be used only 
to measure allergy and will be destroyed at the end of the study. 
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b) From the questionnaire.  
                 There are minimal risks associated with completing the questionnaire. The 
only risk                                           
                 is a loss of confidentiality about personal information but the data will be 
seen only by  
                 study personnel.  All reports will present aggregate data in which 
individuals will not  
                 be  identifiable.   
 
6. Expected benefits to you and others 
 
    Your health will be assessed for free.  
 
    Refreshments will be provided as compensation for time in participating in 
the study. 
 
    This study on the  health effects of pesticides will benefit women living  
    in farming areas and who are exposed to pesticides in the environment.  
Steps can be taken  
    to reduce or prevent exposure to the pesticides or the pesticide can be  
    banned. The blood and urine results can be used to develop ways in which 
the amount of  
    pesticides in your body can be monitored. 
 
7. Costs to you resulting form participation in the study 
 
         The study is offered at no cost to you. 
 
8. Confidentiality of information collected 
 
Study participants will not be personally identified in any reports on this study.  
The records will be kept confidential to the extent provided by law.  The records, 
including any identification information, will be destroyed after the results have 
been fully analysed. 
 
9. Documentation of the consent 
 
One copy of this document will be kept together with our research records on this 
study.  A second copy will be given to you to keep. 
 
10. Contact person. 
 
You may contact the following person for answers to further questions about the 
research, your rights, or any injury you may feel is related to the study. 
 
  Name of person: MA Dalvie (The principal investigator)     telephone 021 
4066610 
  Name of person: Lamees Emjedi (Ethics administrator)     telephone 021 
4066492 
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11.Voluntary nature of participation 
 
Your participation in this project is voluntary. Subsequent to your consent, you 
may refuse to participate in or withdraw from the study at any time without 
penalty or loss of benefits to which you may otherwise be entitled.  
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12. Consent of the participant 
 
I have read the information given above.  I understand the meaning of this 
information.  I hereby consent to participate in the study. 
 
 
____________________________                                 
_______________________   
Printed name of participant     signature  
  
 
 
____________________________                                 
_______________________   
                       Date 
 
 
 
____________________________  _______________________       
___________________ 
Interviewers (print)    signature   
 Date 
 
 
____________________________  _______________________       
___________________ 
 
Witness (print)    signature   
 Date 
 
 
Date:__________________________________________ 
 
 
Study Number __________________ 
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Appendix F2 
Afrikaans Consent Form 
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Toestemming om deel te neem in ‘n opname van ondersoek oor Gesondheids 
gevolge weens blootstelling aan gifstowwe op landlike vrouens in die Weskaap 
 
 
2. Titel van navorsingsprojek  
 
Gesondheids gevolge weens blootstelling aan gifstowwe op landlike vrouens in die 
Weskaap 
 
2.  Name van navorsers 
     Mohamed  Aqiel Dalvie (BSc, Honours, MSc, PhD) 
     Mohamed Jeebhay (MbChB, MMED, PhD) 
     Leslie London (MbChB, MMED, PhD) 
       
3.  Doel van navorsing 
 
    Die Universiteit van Kaapstad is besig met ‘n studie oor die gesondheids gevolge 
weens    
    blootstelling aan gifstowwe op landlike vrouens in die Weskaap. Ons wil graag vir 
u toets. 
    Daar is voordele van hierdie studie vir vrouens wie op plase woon en wie   
    bloodgestel aan gifstowwe is in die algemene omgewing. 
  
 
4. Beskrywing van die navorsingsprojek 
 
    Daar word van u verwag om ŉ urien en 2 bloedmonsters te    
    voorsien en u sal ’n asemhalingstoets ondergaan en u moet ŉ vraelys voltooi. 
   
a) Vraelys:  :  ŉ Lid van ons studie-span sal ŉ ondervhoud in privaat met u 
voer om  
                      die vraelys te voltooi. Daar sal vrae gestel word i.v.m. u 
algemene persoonlike  
                       inligting, u algemene mediese gesondheid en lewenslange 
omgewings-   
                       blootstelling aan gifstowwe.  
 
   b) Urien monster:  U moet ŉ urien-monster (in privaat) in ŉ plastiese houer  
                                 doen en dit aan die verpleegster gee. 
 
 
 c) Bloed monster: ŉ Verpleegster sal 10ml bloed uit een van u are in u  
                                             arm trek. Die bloed sal getoets word vir u allergiese status 
 
d) Asemhalingstoets: U sal ‘n asemhalingstoets ondergaan met ‘n 
verpleegster. 
 
  
11. Gevare(risikos) en ongemaklikhede van die navorsing 
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a) Van die bloed toets: ŉ Enkel steek(prik) van die naald sal gevoel 
word wanneer die   
                         bloed getrek word. Somtyds sal daar ŉ klein kneusplek op die arm 
wees a.g.v. die   
                         naald, maar dit is nie so erg nie en dit sal baie gou gesond raak. Die 
hoeveelheid bloed   
                         wat getrek word is baie min en die liggaam sal dit gou weer vervang. 
Bloedmonsters  
                         sal slegs gebruik word om allergiese probleeme te meet en sal aan die  
                         einde van die studie vernietig word. 
 
 
 
 
 
        b)Van hierdie vraelys.  
Daar is minimale risikios geassosieer met die voltooing van die vraelys. 
Die enige risiko is die verlies van vertroulikheid of werkoefening 
informasie maar die data sal alleenlik by die studie personeelgesien 
word. Alle uitslae bevat gesamentlike data waar individuale nie 
geidentifiseer sal word nie 
 
12. Verwagte voordele aan u en andere 
 
U gesondheid sal gratis bepaal word en ons sal u verwys na ’n publieke 
gesondheids fasiliteit indien ons enige gesondheidsprobleeme geidentifiseer 
het. 
 
      Verversings sal voorgesit word as vergoeding vir u tyd en deelname aan die  
      navorsing (toetsing) 
 
Die studie oor die gesondheids gevolge weens blootstelling aan gifstowwe sal 
baat vind by vrouens wie woonagtig is op plase waar daar blootstelling van 
gifstowwe by die werk en in die omgewing is.Stappe kan geneem word om die 
bloot-stelling van gifstowwe te verminder of die gifstowwe kan verban word. 
Diebloed en die urine uitslae kan gebruik word om maniere te ontwikkel 
waarin die aantal gifstowwe in die liggaam gemonitor kan word.    
 
 
13. Koste aan u as gevolg van u deelneming in die studie 
 
         Die studie word aangebied teen geen koste aan u. 
 
14. Vertroulikheid van inligting wat gekollekteer word. 
 
U naam sal nie op enige van die studie verslae verskyn word nie. Die verslae sal 
vertroulik gehou word tot die uitgestrektheid wat deur die wet voorsien word. Die 
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uitslae, uitsluitende enige identiteits informasie sal vernietig word nadat dit 
heeltemal geanaliseer was. 
 
15. Dokumentasie van toestemming 
 
Een afskrif van die document sal saam met ons navorsingsrekords oor die studie 
gehou word.   
      Die tweede afskrif sal aan u gegee word om te hou. 
 
 
16. Kontak persoon. 
 
U mag een van die volgende persone kontak vir antwoorde tot verder vrae in 
verband met die navorsing, u regte of enige besering wat u voel met die studie 
verband hou. 
 
  Naam van persoon: MA Dalvie (Die hoof navorser)                 telefoon 021 
4066610 
  Naam van persoon: Lamees Emjedi (Etiese administrateur)     telefoon 021 
4066492 
 
17. Vrywilligheid geaardheid van deelname  
 
U deelname aan die projek is vrywillig. U kan teen enige tyd weier om deel te 
neem of onttrek van   
die studie sonder om beboet te word of aan verlies te lui van voordele wat u 
toekom. 
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13. Toestemming van deelnemer 
 
I have read the information given above.  I understand the meaning of this 
information.  I hereby consent to participate in the study. 
 
 
_____________________________________________
 _______________
_______ 
Naam in drukskrif van ouer/ deelnemer (volwassene)           handtekening 
   
 
 
____________________________                                  
Datum 
 
 
 
____________________________     _______________________       
___________________ 
Verslagewer  (drukskrif)      handtekening                               Datum 
 
 
____________________________      _______________________       
___________________ 
getuie (drukskrif)                  handtekening             Datum 
 
 
Datum:__________________________________________ 
 
 
Studie Nommer ________ 
 
Naam ______________________________ 
 
Kontak nommer _______________________ 
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Appendix G 
International Archives of Allergy and Immunology 
Guidelines for authors 
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Guidelines 
Guidelines for Authors 
www.karger.com/iaa_guidelines 
 
Introduction 
Submission 
Types of Papers 
Conditions 
Plagiarism Policy 
Arrangement 
Color Illustrations 
References 
Digital Object Identifier (DOI) 
Supplementary Material 
Author's ChoiceTM, NIH-Funded Research, Self-Archiving 
Page Charges 
Proofs 
Reprints 
 
 
Introduction 
 
'International Archives of Allergy and Immunology' appears monthly and provides a 
forum for publication of work from all aspects of modern allergology and 
immunology. Papers considered of special interest will be treated as 'hot topics' and 
every attempt will be made to publish these especially fast. 
 
The Editor-in-Chief, the Managing Editor and a team of internationally established 
Associate Editors competently covering all fields of allergology and immunology are 
responsible for the scientific quality of this international core journal. 
 
'International Archives of Allergy and Immunology' publishes original work in the 
fields of allergy, immunopathology and transplantation, cellular immunology, 
immunogenetics, immunopharmacology and immunoendocrinology, mucosal 
immunity, immunology of infectious diseases and immunology of connective tissue 
diseases. In addition, reviews, minireviews, commentaries and opinions on 
controversial subjects are published regularly. 
 
A new system of manuscript submission, reviewing and processing guarantees 
competent and fair reviewing as well as fast and high quality publication. 
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Submission 
 
Only papers written in English are considered and should be submitted online: 
 
Online Manuscript Submission 
 
If you have any problems with submission, please contact:  
 
S. Karger AG 
Editorial Office 'International Archives of Allergy and Immunology' 
P.O. Box 
CH–4009 Basel (Switzerland) 
Tel. +41 61 306 1360 
Fax +41 61 306 1434 
E-mail iaa@karger.com 
 
 
 
Types of Papers 
 
Original research papers: Submitted manuscripts should be fully documented 
reports of original research. They must describe significant and original observations 
to be critically evaluated and, if necessary, repeated. 
 
Short communications: These manuscripts should not contain more than 2 printed 
pages (i.e. 5 manuscript pages), including an abstract, essential references and not 
more than 3 tables or figures. Such communications should represent complete, 
original studies and should be arranged in the same way as full length manuscripts. 
 
Novel insights from clinical practice (formerly case reports): the publication space 
available for case reports is very limited. The journal only considers case reports with 
significant new insights or with an extremely unusual and memorable course. 
Highlighted boxes containing one or two bullet points on 'Established facts' (what is 
already known) and 'Novel insights' (what new information has been gained) are 
required and should be placed on the first page of the report. These should be selected 
so as to reinforce the novelty of the clinical observation. 
 
 
Example 
Established Facts 
 
  ·    Already known fact 1 ...       
 
  ·    Already known fact 2 ...  
 
  ·     ... 
 
Novel Insights  
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  ·    New information 1 ...           
 
  ·    New information 2 ...  
 
  ·     ... 
 
 
The manuscript should be presented with an abstract (unstructured, max. 200 words), 
followed by introduction, case report and discussion. Maximum 3 figures. 
 
Review articles, minireviews and commentaries: Authors, who wish to contribute a 
manuscript to one of these categories should contact the Editor-in-Chief. Minireviews 
should be focused, brief reports on topics of current interest. Commentaries should 
offer a more personalized perspective on a topic that will be of interest to the general 
readership. All contributions to these categories will be subject to Editorial review. 
 
Letters to the Editor concerning work published in the journal may be submitted. 
They should not exceed 2 manuscript pages including one table or figure. 
 
 
 
Conditions 
 
All manuscripts are subject to editorial review. Manuscripts are received with the 
explicit understanding that they are not under simultaneous consideration by any other 
publication. 
 
A cover letter with the name, address, and telephone and telefax numbers of the 
corresponding author must accompany each manuscript. This letter must include a 
statement that affirms that all authors concur with the submission. 
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Supplementary Table 1: Urinary pesticide metabolites levels among rural 
women in the Western Cape 
 
Pesticide metabolites Farm dwellers Town dwellers Overall 
Median (interquartile range) 
Corrected for creatinine (µg/g creatinine) 
I. Organophosphate metabolites 
          Dialkyl phosphates (n = 178) 
DAP 141.42(37.4-249.83)  132(45.64-204.45) 133.59(41.86-229.09) 
   DMP   32.91(13.50-55.75)   26.19(14.33-52.36)   29.63(14.06-53.22) 
   DMTP   13.41(3.05-62.45)   36.44(6.11-71.85)   21.87(4.03-65.85) 
   DMDTP     5.70(0.83-51.51)     9.57(0.87-66.22)     6.87(0.85-61.77) 
   DEP     5.01(1.37-12.90)     4.13(0.59-9.47)     4.27(1.08-10.04) 
   DETP     3.70(1.15-26.98)     3.94(1.35-26.18)     3.87(1.20-26.98) 
   DEDTP     1.99(0.55-5.10)     1.70(0.60-8.02)     1.89(0.58-6.44) 
          Chlorpyrifos metabolite (n = 186) 
TCPY     6.15(3.50-10.64)*     4.14(2.70-7.57)     5.16(2.84-9.24) 
II. Pyrethroid metabolites (n = 183) 
Pyrethroids     6.60(3.61-9.96)     5.26(2.74-8.42)     6.01(3.24-9.67) 
   cis-DCCA     0.71(0.27-1.28)     0.56(0.23-1.13)     0.62(0.26-1.24) 
   trans-DCCA     0.85(0.47-1.29)**     0.59(0.28-1.02)     0.70(0.37-1.22) 
   DBCA     0.31(0.05-0.63)     0.30(0.04-0.60)     0.30(0.04-0.62) 
   4F3PBA     0.73(0.31-1.32)     0.70(0.33-1.30)     0.73(0.32-1.32) 
   3PBA     3.61(2.11-6.25)     3.34(2.27-5.92)     3.40(2.18-6.00) 
*p < 0.05; **p < 0.01; TCPY: 3,5,6- trichloropyridinol; DAP: sum of the 6 dialkyl phosphate metabolites; DMP: dimethyl phosphate 
DMTP: dimethyl thiophosphate; DMDTP: dimethyl dithiophosphate; DEP: diethyl phosphate; DETP: diethyl thiophosphate 
DEDTP: diethyl dithiophosphate; Pyrethroids: sum of the 5 pyrethroid metabolites;  
cis-DCCA: cis- 2,2-dichlorovinyl-2,2- dimethylcyclopropane-1-carboxylic acid 
trans-DCCA: trans- 2,2-dichlorovinyl-2,2- dimethylcyclopropane-1-carboxylic acid 
DBCA: cis-2,2-dibromovinyl-2,2-dimethylcyclopropane-1-carboxylic acid; 
4F3PBA: 4-fluoro-3-phenoxybenzoic acid; 3PBA: 3- phenoxybenzoic acid 
Values below LOD were substituted by LOD divided by square root of 2 
 
 
 
 
 
 
 
